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Abstract
The Janus Kinase - Signal Transducer and Activator of Transcription (JAK-STAT)
signaling pathway transduces several signals crucial for development and homeostasis.
Suppressors of cytokine signaling (SOCS) proteins control JAK-STAT signaling via a negative
feedback loop. The transcription factor STAT5 is known to play a significant role in fat cell
development and function, and several studies suggest that acetylation may affect STAT5
transcriptional activity. To test this hypothesis, we treated 3T3-L1 adipocytes with growth
hormone (GH) to activate STAT5 in the presence or absence of histone deacetylase (HDAC)
inhibitors. STAT5 acetylation levels were low in adipocytes and mostly unchanged by the
inhibitors. Still, two STAT5 target genes from the SOCS family, Socs3 and Cish, were inversely
regulated by general and specific HDAC inhibitors (Socs3 expression increased, while Cish
levels decreased). Chromatin immunoprecipitation analyses revealed that changes in total and
activated RNA polymerase II, but not STAT5A binding to Socs3 and Cish promoters highly
correlated with changes in gene expression. Thus, we hypothesized that HDAC inhibitors were
indirectly affecting another protein in the transcriptional complex. Members of the bromodomain
and extra-terminal (BET) protein family bind acetylated histones and recruit transcription
factors, thus playing a role in chromatin remodeling and transcription. Treatment with the BET
inhibitor JQ1 produced the same divergent effects as HDAC inhibition on both Socs3 and Cish
gene expression, as well as on RNA polymerase II binding. Moreover, BET proteins help drive
productive elongation of mRNA by recruiting the positive transcription elongation factor (PTEFb). We found that JQ1, but not the HDAC inhibitor LMK-235, could impact P-TEFb
availability in a manner consistent with the Socs3 gene expression changes we observed. We
propose a model in which GH-induced Cish transcription is dependent on the BET protein,
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BRD2, and susceptible to inhibition by JQ1 (and indirectly by HDAC inhibitors), whereas Socs3
mRNA elongation may involve recruitment of different factors, thus explaining the divergent
effects of HDAC/BET inhibition on the two genes. Overall, our results demonstrate substantially
different transcriptional regulation of Socs3 and Cish, suggesting distinct roles for these two
related proteins in adipocytes.
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Chapter 1. Literature Review
1.1. Adipocytes and adipose tissue
Adipocytes are specialized cells with three principal features. The most well-known is
energy storage in the form of triglycerides. Second, they have the ability to respond to insulin.
Third, they produce hormones that act on other tissues. All of these functions of adipocytes are
important in the regulation of whole-body metabolism, and disruption of any of these roles can
lead to metabolic dysfunction and type 2 diabetes. Regarding the storage of lipids in adipocytes,
it may be intuitive to think that limiting fat accumulation would be beneficial; however,
impairments in adipocyte development and lipid storage lead to ectopic fat accumulation in
other tissues and to unhealthy metabolic states (reviewed in Gastaldelli 2011). The inability to
respond to insulin normally, or insulin resistance, in adipocytes can cause systemic metabolic
dysfunction involving many tissues (reviewed in Sethi and Vidal-Puig 2007). Finally, the
endocrine functions of adipocytes are also crucial contributors to metabolic health. For example,
leptin, a hormone produced exclusively in adipocytes, acts in the brain to suppress food intake;
adiponectin, another fat-specific hormone, regulates whole-body insulin sensitivity.
Historically, adipocytes have been divided into two main types, white or brown
adipocytes, possessing different morphology and functions. White adipocytes are characterized
by a single large cytoplasmic lipid droplet that pushes the nucleus to the periphery of the cell;
their central function is to store lipid. Brown adipocytes have multiple lipid droplets and a darker
color because of higher mitochondrial content; they dissipate energy and produce heat in a
process called non-shivering thermogenesis, which is facilitated by uncoupling protein 1 (UCP1) (reviewed in Saely, Geiger, and Drexel 2012; reviewed in Jacqueline M Stephens 2012).
1

Rodents and other small mammals have a considerable amount of brown adipose tissue (BAT),
while larger mammals generally lose their BAT in the early years of life. More recently, another
type of fat cell has been described as a “beige” or “brite” adipocyte. Beige adipocytes are also
thermogenic, but differently from brown adipocytes, they are located in white adipose tissue
(WAT). The origin of beige adipocytes is controversial; some studies show they originate from
unique precursors (Wu et al. 2012), while there is also evidence that they derive from white
adipocytes (Cinti 2012). Unlike brown adipocytes, beige adipocytes are present throughout
adulthood and are thought to be viable targets for anti-obesogenic therapies (Wu et al. 2012).
There are many adipose tissue (AT) depots with distinct anatomical locations and
functions. Some researchers even support the idea that each fat depot should be considered a
different tissue (reviewed in Kruglikov and Scherer 2016). In humans, visceral fat, upper body
abdominal subcutaneous fat, and lower body subcutaneous fat constitute the three main adipose
depots. In rodents, the most commonly used pre-clinical model to study human obesity, fat
depots are differently distributed and great caution must be used in translating findings from
rodents to humans (reviewed in Chusyd et al. 2016). Subcutaneous adipose tissue is considered a
metabolic sink for storage of excess lipid that could be deleterious when present in circulation or
in other non-adipose tissues. Visceral fat accumulates around internal organs and is commonly
believed to be the predominant contributor to metabolic dysfunction (reviewed in Gastaldelli et
al. 2002). Thus, diseases like diabetes, atherosclerosis, and hypertension are more prevalent in
individuals with higher waist-to-hip ratios (indicative of higher amounts of visceral fat).
Conversely, people with relatively higher levels of gluteofemoral body fat may be protected from
obesity-associated diseases (reviewed in Manolopoulos, Karpe, and Frayn 2010).
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Adipose tissue is not only composed of adipocytes. Other cell types present in AT
include endothelial cells, preadipocytes, and immune cells such as macrophages, neutrophils, and
lymphocytes. The combination of all non-adipocyte cell types in AT is called the stromovascular
fraction (SVF). Obesity is associated with increased macrophage and T lymphocyte infiltration
within adipose tissue (Weisberg et al. 2003; Kintscher et al. 2008), and there is substantial
evidence that inflammation and decreased insulin sensitivity in AT contribute to whole-body
insulin resistance (reviewed in Surmi and Hasty 2008).
In addition to being a source of classical endocrine factors, recent studies have shown
that AT can produce and secrete microRNAs (miRNAs). These miRNAs are single-stranded
noncoding RNAs of about 19-22 nucleotides in length that can negatively regulate translation in
other tissues by decreasing target mRNA levels. The majority of adipose tissue-derived miRNAs
is secreted in exosomes, which are extracellular vesicles (EVs) of about 50–200nm (Thomou et
al. 2017). miRNAs play a role in the development and function of many cells, and computational
calculations predict that a single miRNA regulates hundreds of different mRNAs (reviewed in
Dumortier, Hinault, and Van Obberghen 2013). Variations in miRNA levels can be can be
beneficial or detrimental. Increased levels of specific miRNAs have been correlated with several
diseases such as cancer (Hata and Lieberman 2015), diabetes (Trajkovski et al. 2011) and
cardiovascular disease (Caroli et al. 2013). Moreover, adipose-derived miRNAs decrease with
age, and this process can be reversed by caloric restriction (Mori et al. 2012). Thus, miRNAs can
be considered a new type of endocrine mediator that plays significant roles in the regulation of
metabolism.
A variety of murine cell models have been used to study adipocyte development and
function, including mesenchymal stem cells (MSCs) and preadipocyte lineages. Adipogenesis
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can be divided into two main steps: commitment and terminal differentiation. MSCs are not
committed to adipocyte lineage and therefore, depending on external stimuli can differentiate
into numerous cells types such as myocytes, chondrocytes, and adipocytes. The most commonly
used cell line from this category is C3H10T1/2 stem cells. Among the most commonly used
preadipocyte cell lines are the 3T3-L1, 3T3-F422A, OP9, and 1246 cell lines. These types of
cells are already committed to the adipocyte lineage and cannot differentiate into other cell types
(reviewed in Ruiz-Ojeda et al. 2016). To better promote preadipocyte differentiation, researchers
use specific hormonal cocktails for each of the different cell lines. The differentiation cocktails
for 3T3-L1 and 3T3-F422A preadipocytes contain 3-isobutyl-1-methylxanthine (MIX),
dexamethasone (DEX), and insulin. High levels of cyclic AMP (cAMP) are important for
differentiation, and MIX promotes adipogenesis by inhibiting the enzyme that degrades cAMP.
DEX, a glucocorticoid receptor agonist, induces transcription of genes necessary for
adipogenesis. Lastly, insulin is an anabolic hormone which promotes lipid storage (Grenn and
Meuth 1974; Green and Kehinde 1976). These various in vitro cell models are valuable tools to
study adipocyte differentiation and alterations in lipid storage, insulin sensitivity, and adipokine
secretion, which are the main functions of fat cells.
1.2. Transcription factors
Cells express selected genes in response to stimuli such as stress, hormones, cytokines,
growth factors, and infections. In addition, cell type-specific gene expression regulation is what
makes an adipocyte have a completely different form and function from a neuron, for example.
Transcription factors play a major role in gene regulation; they bind to specific DNA response
elements and can promote or repress gene expression. Transcription factors are categorized by
the structural motifs in their DNA-binding domains. The most common motifs are helix-turn4

helix (HTH), helix-loop-helix (HLH), zinc finger (ZNF), or leucine zipper (reviewed in
Papavassiliou 1995). The most thoroughly described motif is HTH, which contains two α-helices
separated by a β-turn. Despite some variability, this motif is highly conserved throughout
species. More recent studies have revealed that HTH domains are not only transcriptional
regulators, but that they can also play a role in DNA repair, RNA metabolism, and even mediate
protein-protein interactions (reviewed in Aravind et al. 2005). HLH transcription factors are
crucial in several development pathways, such as neurogenesis, myogenesis, and sex
determination. These proteins have two important regions, one comprising many basic residues
that allow HLH to bind to DNA, and another containing mostly hydrophobic residues allowing
HLH to form homodimers and/or heterodimers (reviewed in Murre et al. 1994). Zinc finger
proteins are characterized by different combinations of cysteine and histidine residues
coordinated by a zinc ion. Structural studies show that typical zinc-finger domains have two βsheets and one α-helix. In addition to transcriptional regulation, ZFPs are involved in ubiquitinmediated protein degradation, DNA repair, cell migration, among others (reviewed in Cassandri
et al. 2017). Leucine zipper proteins contain four or five leucine residues spaced exactly seven
residues apart and positioned on the outer portion of α-helices, permitting the interaction with
another α-helix and providing a structural basis for dimerization. Several well-known
transcription factors such as C/EBP, Fos, Jun and c-Myc are characterized by leucine zipper
domains (reviewed in Struhl 1989; reviewed in Busch and Sassone-Corsi 1990).
In addition to DNA binding domains, transcription factors often have activation domains.
Unlike DNA binding domains, which are very specific structures and bind to determinate DNA
sequences, activation domains have more variable configurations. Early studies revealed that
activation domains are composed of acidic residues that may act to form amphipathic α-helices.
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However, not all activation domains are defined by acidic residues; some contain glutamine- and
proline-rich motifs. Activation domains of transcription factors largely recruit other proteins to
promote transcription. Moreover, these domains act synergistically. Therefore, two activation
domains have stronger effects than either one acting separately (reviewed in Ptashne 1988;
reviewed in Tasset et al. 1990).
1.3. JAK-STAT signaling pathway
The Janus kinase-signal transducers and activators of transcription (JAK-STAT)
signaling pathway can be activated by a variety of growth factors and cytokines. The pathway
transduces several signals critical for developmental and homeostatic processes, being critical to
immune development, hematopoiesis, mammary gland development and adipogenesis.
Typically, when a hormone or cytokine binds to its receptor, membrane-bound receptor proteins
JAKs are brought together allowing transactivation by phosphorylation. Activated JAKs then
phosphorylate STATs, permitting dimerization of STATs through their conserved SH2 domains.
These activated STATs translocate to the nucleus and bind to response elements of targets genes,
promoting or repressing their expression (reviewed in Rawlings, Rosler, and Harrison 2004). In
mammals, there are four members in the JAK family (JAK1, JAK2, JAK3 and TYK2).
The STAT family, originally discovered in studies on IFNγ signaling (Shuai et al. 1992),
is composed of 7 members: STATs 1, 2, 3, 4, 5A, 5B and 6. STAT proteins share six functional
domains (Fig. 1.1): N-terminal, coiled-coil, DNA binding, linker, SH2 and transactivation
domains. The N-terminal domain is important for dimerization with another STAT, while coiledcoil and transactivation domains interact with other proteins. The linker is involved in
transcription activation. The SH2 domain is essential for receptor association (Lim and Cao
2006). The DNA binding domain recognizes palindromic DNA sequences, represented by
6

TTN5AA or TTN6AA, in the promoters of target genes (Decker and Kovarik 1999). In addition
to being phosphorylated by JAKs, STATs are known to be regulated by other post-translational
modifications including ubiquitination (T. K. Kim and Maniatis 1996), SUMOylation (Rogers,
Horvath, and Matunis 2003; Ungureanu et al. 2005), methylation (Rho et al. 2001), and
acetylation (Shankaranarayanan et al. 2001; R. Wang, Cherukuri, and Luo 2005).

N

CC

DNA

LK

SH2

TA

Figure 1.1. Functional domains of STAT proteins. N = N-terminal, CC = coiled-coil, DNA =
DNA binding domain, LK = Linker domain, SH2 = SH2 domain, TA = transactivation domain.
The JAK-STAT signaling pathway is regulated by a class of proteins called suppressors
of cytokine signaling (SOCS), which participate in a negative feedback loop to prevent sustained
activation. SOCS proteins share a SH2 domain and a SOCS box at the C-terminus. The SH2
domain determines the target of each SOCS protein, and the SOCS box is known to associate
with members of the ubiquitin ligase family, responsible for protein degradation (reviewed in
Krebs and Hilton 2001; reviewed in Chikuma et al. 2017). SOCS proteins were first discovered
by three independent groups (Naka et al. 1997; Endo et al. 1997; Starr et al. 1997), and a DNA
database search revealed at least 20 proteins in mice and humans that share the SOCS box
domain, but only proteins that contain both the SH2 and SOCS domains are named SOCS
proteins (Hilton et al. 1998). The SOCS family is composed of SOCS1-7 and CISH, which was
originally cloned in hematopoietic cell lines (Yoshimura et al. 1995). SOCS1, SOCS2, SOCS3
and CISH are the most thoroughly characterized proteins in the family. SOCSs are highly
regulated at the transcriptional level by STATs; they are rapidly transcribed and translated, and
they negatively regulate JAK-STAT pathway activation (reviewed in Trengove and Ward 2013).
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1.4. Histone Deacetylases (HDACs) and HDAC inhibitors
The activity of an enzyme that catalyzes the removal of acetyl groups from lysine
residues of proteins was first described in calf thymus extract (Inoue and Fujimoto 1969).
Numerous studies followed that discovery, and since these enzymes were initially found to
remove the acetyl groups from histones, they were called histone deacetylases (HDACs). Several
years later, the first non-histone protein, p53, was described to be lysine acetylated (Gu and
Roeder 1997). Thus, they are also called lysine deacetylases (KDACs). HDACs play important
roles in histone modulation and in the regulation of gene expression. Currently, the HDAC
superfamily is divided in four classes. Class I consists of HDAC1, 2, 3 and 8, which are
homologous to the yeast deacetylase RPD3 protein. These HDACs are expressed ubiquitously
and are localized mainly in the nucleus (reviewed in Taunton, Hassig, and Schreiber 1996).
HDAC1 and 2 are highly homologous and have been described to be part of repressive
complexes such as sin3, nucleosome remodeling and deacetylase (NuRD) and REST corepressor
1 (CoREST). HDAC3 is found in other repressive complexes, the nuclear receptor corepressor
(N-CoR) and silencing mediator of retinoic acid and thyroid hormone receptors (SMRT), while
HDAC8 has not been shown to be involved in any repressor complex (reviewed in Haberland,
Montgomery, and Olson 2009). Class II members are similar to yeast HDA1 protein. They are
subdivided in Class IIa, which is comprised of HDAC4, 5, 7 and 9, and class IIb, which includes
HDAC6 and 10. Class IIa HDACs have larger N-terminal portions and possess autonomous
repressor activity (X. Zhou et al. 2000). Moreover, they have low catalytic activity and are
commonly found in complexes with the class I HDACs (Fischle et al. 2002a; Jones et al. 2008).
Class IIb is composed of HDACs 6 and 10 because they are evolutionarily closely related.
However, HDAC6 is unique within the HDAC family since it is the only member possessing two
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catalytic domains in tandem. Class IV is composed only of HDAC11, since its sequence
similarity with other HDACs is limited. In addition, HDAC11 is not known to participate in any
repressor complex, possibly suggesting a distinct role for this member (Reviewed in De Ruijter
et al. 2003).
In contrast to classical HDACs, which are zinc-dependent, class III deacetylases are
NAD+-dependent. They are called silent information regulator two (Sirt) proteins or sirtuins and
were first identified in studies on yeast that showed they were necessary for telomeric silencing
effects (Pillus and Rine 1989; Gottschling et al. 1990). Some years later, sirtuins were
demonstrated to be involved in the repair of double-strand DNA breaks, cell-cycle progression,
and in the molecular mechanisms of ageing in several species (Mills, Sinclair, and Guarente
1999; Tissenbaum and Guarente 2001). In mammals, seven sirtuins have been described, and
they are separated in classes I to IV. Even though they are highly conserved, sirtuins have
diverse biological functions and unique binding partners and substrates (reviewed in North and
Verdin 2004; reviewed in Haigis and Sinclair 2010).
HDAC activity is counterbalanced by another class of enzymes called histone acetyl
transferases (HATs) or lysine acetyl transferases (KATs) that are responsible for adding acetyl
groups to histones and non-histone proteins. Acetylation is an especially interesting modification
because it connects cell metabolism to epigenetics, and altered HDAC and HAT activities have
been associated with numerous types of cancer (R. J. Lin et al. 1998; L. Wang et al. 2011;
Holmlund et al. 2013; Zhong et al. 2018). In fact, HDAC inhibitors were discovered empirically
by screening for drugs that promoted tumor cell differentiation (Leder and Leder 1975); only
later were HDACs revealed as their molecular targets. HDAC dysfunctions have also been
connected with neurological diseases such as Alzheimer’s and Parkinson’s diseases (Guan et al.
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2009; Gräff et al. 2012), as well as immune diseases (Glauben and Siegmund 2011; Regna et al.
2014).
Moreover, HDACs have been found to play a role in metabolic diseases. HDAC3
inhibition was shown to regulate PPARγ acetylation and activity, increasing glucose uptake in
white adipose tissue and improving insulin sensitivity in diet-induced obese (DIO) mice (Jiang et
al. 2014). In another study, HDAC9 expression was increased with DIO and impaired adipocyte
differentiation. The deletion of HDAC9 resulted in improved insulin sensitivity and decreased
weight gain and hepatic steatosis (Chatterjee et al. 2014). HDACs have also been described to
repress the formation of type I myofibers in skeletal muscle, affecting insulin mediated glucose
uptake (Potthoff et al. 2007).
The importance of HDACs in the control of gene expression and their involvement in
diseases states has led to the discovery of natural and synthetic HDAC inhibitors. HDAC
inhibitors can be classified in five groups: hydroxamic acids, cyclic peptides, aliphatic acids,
benzamides and sirtuin inhibitors. The first natural hydroxamic acid found to inhibit HDACs was
trichostatin A (TSA) (Yoshida et al. 1990). While TSA is mostly used in laboratory experiments
because of its toxicity, vorinostat (suberoylanilide hydroxamic acid, SAHA) was the first
hydroxamic acid inhibitor to be approved by the United States Food and Drug Administration
(FDA) for the treatment of relapsed and refractory cutaneous T-cell lymphoma (CTCL) (Duvic
et al. 2007). Later, two other inhibitors from this class, belinostat and panabiostat, were approved
by the FDA for the treatment of peripheral T-cell lymphoma and multiple myeloma,
respectively. Several other HDAC inhibitors such as resminostat, rocilinostat and practinostat are
currently in clinical trials (reviewed in Eckschlager et al. 2017). The class of cyclic peptides is
characterized by a complex structure; the most well-known is depsipeptide (romidepsin) which
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was approved by the FDA to treat CTCL in 2009. The aliphatic acids such as valproic acid
(VPA), butyric acid and phenylbutyric acid are relatively weak inhibitors. VPA is used for the
treatment of epilepsy, bipolar disorders and migraines and is currently the subject of clinical
trials for cancer, along with other aliphatic acids. Benzamides mostly inhibit class I HDACs;
entinostat (MS-275-SNDX-275) and tacedinaline (CI994) are currently in clinical trials for a
variety of cancers (reviewed in Kim and Bae 2011; reviewed in Eckschlager et al. 2017). Sirtuin
inhibitors include the pan-inhibitor nicotinamide and the specific SIRT1 and SIRT2 inhibitors
sirtinol, cambinol, and EX-527 (reviewed in Lavu et al. 2008).
The lack of specificity of most HDAC inhibitors is an obstacle in studies to assess HDAC
function and efforts are ongoing to develop inhibitors that effectively target individual HDACs.
Structurally, inhibitors of classical HDACs are characterized by a zinc binding group (ZBG),
connected to a linker that mimics the lysine side chains of HDAC substrates. The chain is
followed by a connecting unit (CU) that can be adapted to improve interactions and it is
terminated by a functional “cap” group (Fig. 1.2.) (reviewed in Roche and Bertrand 2016). To
date, the only selective HDAC inhibitor approved by the FDA is romidepsin, which strongly
inhibits HDAC1 and 2. Other selective class I HDAC inhibitors such as entinostat (MS-275),
tacedinaline (CI-994), and CHR-3996 are currently in clinical trials. Regarding class II
inhibitors, the HDAC6 inhibitor Ricolinostat (ACY-1215) is in clinical trials, and thus far all
selective class IIa inhibitors are in the preclinical phase (reviewed in Li and Seto 2016).

Cap

Linker

CU

ZBG

Figure 1.2. Structure of Zn+-dependent HDAC inhibitors. Cap = Cap group, CU = Connecting
unit, Linker = Hydrophobic linker, ZBG = Zinc-binding group.
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1.5. RNA polymerase II transcription
Transcription is divided into four main steps: transcription initiation, early elongation,
productive elongation and termination. Transcription initiation involves dissociation of doublestranded DNA, the recruitment of RNA polymerase II to a promoter, and the recruitment of
general transcription factors (GTFs). GTFs are required for the formation of the pre-initiation
complex (PIC), which consists of TFIIB, TFIID (which includes the TATA-binding protein,
TBP), TFIIE, TFIIF, TFIIH and Pol II. PIC drives basal transcription (reviewed in Nechaev and
Adelman 2011), while activated transcription is dependent on additional signals that recruit
specific transcription factors to response elements in gene promoters and/or enhancers.
The transition between initiation and early elongation involves the phosphorylation of the
C-terminal domain (CTD) of RNA polymerase. The CTD contains a consensus sequence,
YSPTSPS, that can be phosphorylated on several residues. When the polymerase binds to a
promoter, it is phosphorylated at Serine-5 by CDK7, the catalytic subunit of TFIIH. This event
facilitates polymerase promoter escape. The transition from promoter proximal paused RNA
polymerase to productive elongation is initiated by the recruitment of positive transcription
elongation factor b (P-TEFb), whose predominant form is composed of two catalytic CDK9
subunits and two regulatory Cyclin T1 subunits. P-TEFb phosphorylates Serine-2 residues of
CTD, as well as the negative elongation factor (NELF) and the DRB sensitivity inducing factor
(DSIF). After phosphorylation, NELF is displaced from Pol II and DSIF is converted to a
positive elongation factor, allowing productive elongation to occur (reviewed in Nechaev and
Adelman 2011; reviewed in Adelman and Lis 2012). The final step of termination can occur via
different mechanisms. However, most Pol II mRNA transcripts use the canonical pathway of
cleavage and polyadenylation machinery (reviewed in Nechaev and Adelman 2011).
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The transition between early and productive elongation has emerged as a crucial step in
the expression of most active genes that are highly regulated by P-TEFb. Studies have shown
that P-TEFb availability is highly coordinated by interactions between positive and negative
regulators. P-TEFb is inactive when associated with the small non-coding RNA 7SK and
hexamethylene bisacetamide (HMBA) inducible protein 1 (HEXIM1). HEXIM1 is responsible
for inhibiting the kinase activity of CDK9, while snRNA 7SK stabilizes the HEXIM1-P-TEFb
interaction (He, Pezda, and Zhou 2006). Once dissociated from its inhibitory complex, P-TEFb
can be recruited by other proteins. Among the positive regulators is the super elongation
complex (SEC). SEC is composed of members from the AF4/FMR2 (AFF) family and members
of the eleven-nineteen Lys-rich leukemia (ELL) family of RNA polymerase II (Pol II) elongation
factors. Rapid transcriptional activation in the presence or absence of paused Pol II has been
recognized as a SEC function (reviewed in Luo, Lin, and Shilatifard 2012). In addition to SEC,
bromodomain and extra-terminal domain (BET) protein 4 (BRD4) is known to interact with PTEFb via BRD4 bromodomains or a C-terminal P-TEFb interacting domain (PID) (Jang et al.
2005). Studies suggest that the bromodomains bind to acetylated Cyclin T1 while PID plays a
role in the dissociation of P-TEFb from HEXIM1. In addition to P-TEFb, BET proteins can
recruit transcription factors to gene enhancers and promoters and positively regulate gene
expression (Schröder et al. 2012).
1.6. Bromodomain and Extra-Terminal Domain (BET) proteins
Bromodomain and Extra-Terminal Domain (BET) proteins are called readers because
they bind to acetylated histones or other proteins and regulate chromatin remodeling and
transcription elongation. In mammals, there are four members in the family, BRD2, BRD3 and
BRD4, which are ubiquitously expressed, and the testis-specific BRDT. They are distinct from
13

other bromodomain-containing proteins (BCPs) because in addition to two conserved
bromodomain motifs in the N-terminal region, they also possess in the C-terminal side an extraterminal domain that facilitates additional protein-protein interactions (reviewed in Florence and
Faller 2001). Both BRD2 and BRD4 have been shown to play critical roles in development.
BRD2 null mice have neural tube defects and embryonic lethality (Gyuris et al. 2009), while
BRD4 null mice embryos presented postimplantation lethality (Houzelstein et al. 2002). To date,
no BRD3 KO mouse has been described. In the context of fat cells, BET inhibition has been
reported to inhibit adipogenesis (Goupille et al. 2016).
Like HDAC inhibitors, BET inhibitors have been extensively investigated for the
treatment of cancer and inflammatory diseases. In 2010, JQ1 was the first BET inhibitor to be
described; it competitively binds to bromodomains and prevents BET proteins from binding to
acetylated histones. Only (+)-JQ1 interacts with bromodomains, its stereoisomer (−)-JQ1 does
not inhibit BET proteins. In that study, JQ1 promoted differentiation and growth arrest in
squamous carcinoma (Filippakopoulos et al. 2010). In another study, the inhibitor I-BET
exhibited anti-inflammatory properties in activated macrophages (Nicodeme et al. 2010).
Currently, several BET inhibitors are in clinical trials for the treatment of a variety of cancers
(reviewed in Stathis and Bertoni 2018).
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Chapter 2. Introduction
Obesity, which is the consequence of an imbalance between caloric intake and energy
expenditure, has nearly tripled worldwide since 1975. According to the World Health
Organization (WHO), 39% of adults aged 18 years or older were overweight in 2016 and 13%
were obese. The majority of the world’s population lives in countries where obesity kills more
people than underweight (“World Health Organization; Obesity and Overweight rates” 2016).
The increase of obesity has been followed by the development of obesity-associated health
problems including type 2 diabetes mellitus (T2DM), cardiovascular diseases, stroke, fatty liver
disease, and some types of cancers (Aronne 2002). The prevalence of diabetes worldwide among
adults rose from 4.7% in 1980 to 8.5% in 2014 (“World Health Organization; Diabetes” 2014).
In the US, about 9.4% of the population had diabetes in 2015, with T2DM accounting for 90 to
95% of all diabetes cases (for Disease Control 2017).
Although obesity contributes to the development of several diseases as cited above, this
fact is not the complete story. Some normal weight individuals with low subcutaneous but high
visceral fat mass are at higher risk for T2DM, while insulin sensitive healthy people with obesity
are protected from metabolic syndrome (Klöting et al. 2010). Therefore, studying adipocyte
physiology, metabolism and molecular mechanisms involved in metabolic disease states is
critical to better understand the pathology of T2DM and develop new therapeutics to treat the
disease.
The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) is known to induce
insulin resistance by decreasing expression of several proteins important for the insulin signaling
pathway, including glucose transporter type 4 (GLUT4), CCAAT/enhancer-binding protein-
(C/EBP, and the insulin receptor (IR) (J M Stephens and Pekala 1991; Jacqueline M. Stephens,
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Lee, and Pilch 1997). In 1993, it was shown that TNFα expression is elevated in adipose tissue in
conditions of obesity and was associated with insulin resistance, or the failure to respond to
normal concentrations of circulating insulin (Hotamisligil, Shargill, and Spiegelman 1993). Since
then, other inflammation markers such as interleukin-6 (IL-6) (Bastard et al. 2002), C-reactive
protein (Pradhan et al. 2001) and monocyte chemoattractant protein-1 (MCP-1) (Kanda et al.
2006) have been liked to insulin resistance in adipose tissue and to an increased risk of
developing T2DM. In addition to pro-inflammatory cytokines such as TNF-α, IL-6 and MCP-1
that are largely produced in immune cells found in adipose tissue, there are endocrine hormones
such as adiponectin and leptin that are produced and secreted from adipocytes.
Paradoxically, serum adiponectin levels are decreased with obesity and are positively
associated with insulin sensitivity (Arita et al. 1999). Adiponectin’s insulin-sensitizing actions
are accomplished by three different mechanisms. In skeletal muscle, adiponectin upregulates
genes involved in fatty acid transport, including CD36 and acyl-coenzyme A oxidase. Also, this
hormone activates peroxisome proliferator-activated receptor-α (PPARα) in skeletal muscle and
liver, increasing fatty-acid utilization. Lastly, adiponectin activates adenosine monophosphate
protein kinase (AMPK), stimulating glucose utilization and β-oxidation (reviewed in Yadav et al.
2013). Leptin was discovered in 1994 through positional cloning in ob/ob mice, an obesity
mouse model resulting from a random mutation at Jackson Laboratory (Y. Zhang et al. 1994).
These animals were extremely obese, hyperphagic, diabetic and infertile; they were found to be
deficient in a circulating factor identified as leptin. Since leptin acts in the brain to suppress food
intake, initially it was thought that leptin administration could be a promising therapy for obesity.
However, leptin levels are directly correlated with body fat and obese humans develop leptin
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resistance, which reveals the complexity of hormone regulation and metabolism (reviewed in
Kelesidis et al. 2010).
As previously mentioned, one of the functions of adipocytes is energy storage in the form
of triglycerides. The equilibrium between adipose tissue lipolysis and lipogenesis is an important
factor for metabolic health. Obesity is associated with increased basal lipolysis in AT and a
resulting elevation in circulating free fatty acids (FFA). Higher FFA levels are accompanied by a
decrease in whole-body glucose utilization (reviewed in Randle 1998) and by impaired beta cell
function and insulin secretion (Oprescu et al. 2007).
Expansion of adipose tissue occurs through both increases in cell size (hypertrophy) and
increases in cell numbers (hyperplasia). Since hyperplasia results from cell proliferation and
mature adipocytes do not divide, preadipocyte differentiation, or adipogenesis, is required for
adipose tissue hyperplasia. Adipogenesis is controlled by several factors from hormones to
cytokines and signaling cascades. One of the most studied areas of adipogenesis is the
transcriptional control of this highly elaborate cellular process. The nuclear receptor peroxisome
proliferator activated receptor gamma (PPARγ) is the major regulator of adipogenesis.
Moreover, members of the CCAAT/enhancer-binding proteins (C/EBPs) family also play a
pivotal role in adipocyte differentiation (reviewed in de Sá et al. 2017).
In addition to PPARγ and C/EBPs, the STAT transcription factors are important for
adipocyte development and function. STATs regulate gene expression in a tissue-specific
manner. In fat cells, STATs 1, 3, 5A, 5B and 6 are expressed. STATs 1, 3, 5A and 5B are
regulated during adipocyte differentiation while STAT6 levels stay constant (J M Stephens,
Morrison, and Pilch 1996). Of the STATs expressed in adipocytes, STAT5 plays a prominent
role in adipocyte differentiation and function, and it has been the focus of the Stephens
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laboratory. When STAT5 was originally discovered as a regulator of the β-casein gene, it was
called mammary gland factor (MGF) (Schmitt-Ney et al. 1991). STAT5A and 5B derived from a
duplication event and therefore are highly homologous; most differences are in the C-terminal
region in which STAT5A is a little longer (Yaming Wang and Levy 2012).
The importance of STAT5 for adipocyte differentiation has been demonstrated in several
ways. In one study, ectopic expression STAT5A was sufficient to promote adipogenesis in
BALB/c and NIH-3T3 non-precursor cells, and STAT5B enhanced STAT5A-induced
adipogenesis (Floyd and Stephens 2003). Moreover, constitutively active STAT5A was able to
substitute for GH-dependent differentiation of 3T3-F442A preadipocytes (Shang and Waters
2003). In vivo studies demonstrated that mice lacking only STAT5A or 5B had abnormal adipose
tissue and mice lacking both STAT5A and 5B were more severely affected (Teglund et al. 1998).
Since these are global knockouts, however, the effects of STAT5 deletion might be due to
developmental issues and do not explore the role of STAT5 in adipocytes. More recently,
Kaltenecker and colleagues have generated a knockout (KO) mouse that lacks STAT5 only in
mature adipocytes. These mice presented increased insulin sensitivity and adiposity as well as
decreased lipolysis rate (Kaltenecker et al. 2017). In our own studies, adipose-specific STAT5
KO mice are also more insulin sensitive, and they also exhibited higher adiposity compared to
control mice. However, we saw no effects of the KO on lipolysis (RICHARD et al. 2018).
Although it is largely speculated that mice with reduced growth hormone signaling are obese due
to a loss of lipolysis, further studies are needed to confirm these speculations.
In addition to the generation of adipose-specific STAT5 KO mice, the identification of
novel STAT5 interacting proteins is another approach to try and understand the functions of
STAT5 proteins in adipocytes. To conduct this analysis, STAT5 was immunoprecipitated from
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mature 3T3-L1 adipocytes and the precipitate was analyzed by mass spectrometry. Surprisingly,
pyruvate dehydrogenase complex (PDC) was found to interact with STAT5 in the adipocyte
nucleus (Richard, Hang, and Stephens 2017). PDC is normally found in the mitochondrial matrix
where it catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA (reviewed in Wieland
1983). The presence of PDC in the nucleus is a recent observation. In a study in cancer cells,
PDC was able to produce acetyl-CoA in the nucleus and modulate histone acetylation (Sutendra
et al. 2014). Another study in prostate cancer cells, have shown that nuclear PDC was
responsible for controlling the expression of sterol regulatory element-binding transcription
factor (SREBF)-target genes by mediating histone acetylation (Chen et al. 2018). Thus, the
interaction between STAT5 and PDC in the nucleus of mature 3T3-L1 adipocytes led us to
hypothesize that PDC could be generating acetyl-CoA for acetylation of STAT5 or histones, or
otherwise regulating the function of other proteins in the STAT5 transcriptional complex.
Currently, the role of acetylation in STAT5 transcriptional activity is still unclear. The
majority of studies have established a positive relationship between STAT5 acetylation and its
ability to regulate transcription. In one study, acetylation of the prolactin receptor (PRLR)
affected its dimerization and phosphorylation as well as the subsequent activation of STAT5 by
acetylation (Ma et al. 2010). In another study, STAT5A SUMOylation inhibited acetylation
through competing with the lysine 696 and decreased STAT5A transactivation activity (Van
Nguyen et al. 2012). In addition, prolactin-mediated transcriptional activity of STAT5A and 5B
was enhanced by their interaction with the HAT protein p300/CBP (CAAT-binding protein)
(Pfitzner et al. 1998). However, other studies indicate that HDAC inhibitors, which increase
acetylation levels in the cell, prevent induction of STAT5 target genes (Rascle, Johnston, and
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Amati 2003). In addition, mutations on multiple STAT5 lysine residues did not alter STAT5
transcriptional activity (Pinz et al. 2015a).
At the outset, the objective of this project was to investigate the role of acetylation in
STAT5 transcriptional activity in mature 3T3-L1 adipocytes. To explore this topic, we chose two
main approaches. The first was to assess the modulation of STAT5 acetylation by HDAC
inhibition, and the second was to analyze the effects of HDAC inhibitors on the expression of
STAT5 target genes. Our initial experiments determined that STAT5 acetylation was barely
detectable in mature 3T3-L1 adipocytes, and in experiments where STAT5 acetylation was
detected, it was only modestly regulated by HDAC inhibitors. We had planned to knock down
the wild-type STAT5 and knock in STAT5 mutated at different lysine residues, then analyze
STAT transcriptional activity by STAT5 promoter element luciferase assay. This would have
determined whether acetylation of one specific residue was responsible for STAT transactivation
and whether regulation of STAT5 target genes would be affected by these mutations. This first
part of the project was not performed because we concluded that STAT5 acetylation levels in
mature 3T3-L1 adipocytes were very low and thus unlikely to play a major role in STAT5
transcriptional activity.
In fat cells, STAT5 is activated by growth hormone (GH) or prolactin (PRL) (Zvonic et
al. 2003; Fleenor, Arumugam, and Freemark 2006). Thus, our second approach consisted of
treating mature 3T3-L1 adipocytes with GH and examining the expression of some genes that are
activated by STAT5, such as insulin growth factor 1 (IGF-1) and insulin-like growth factorbinding protein-3 (IGFBP-3) (Woelfle and Rotwein 2004; Hochberg et al. 2015), as well as
members of the suppressors of cytokine signaling (SOCS). We also investigated the regulation of
B-Cell Lymphoma 6 (BCL6) gene, which is inhibited by STAT5 (G. Lin et al. 2014). In
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addition, adipocytes were treated with HDAC inhibitors to modulate acetylation levels in the
cell. The results demonstrated that HDAC inhibitors greatly affected the expression of two
members of the SOCS family. The inhibitors decreased STAT5-mediated upregulation of Cish,
while induction of Socs3 was substantially increased. This opposite modulation has been
reported previously in separate experimental contexts (Pinz et al. 2015b; Xiong et al. 2012), but
this divergent regulation of STAT5 target genes by HDAC inhibitors in the same cells under the
same conditions is a novel finding.
These effects on Cish and Socs3 gene expression were not recapitulated when HDACs
were knocked down using siRNA. Therefore, we hypothesized that the function of other proteins
were being affected by HDAC inhibition, possibly members of the BET protein family. Indeed,
inhibition of BET proteins by JQ1 resulted in the same divergent regulation of Socs3 and Cish as
HDAC inhibition. In fact, studies demonstrate that HDAC and BET inhibitors induce and
repress similar genes (Bhadury et al. 2014). In our studies, chromatin immunoprecipitation
(ChIP) analysis demonstrated that changes in STAT5A binding to the promoter region of Socs3
and Cish did not necessarily correlate with changes in gene expression. However, differences in
binding of the BET protein BRD2 to the transcription start sites and binding of RNA polymerase
II to the coding region strongly correlated with changes in gene expression.
While the inhibition of BET proteins can be readily associated with reduced
transcriptional elongation and consequently decreased gene expression; increased gene
expression by BET inhibition is more challenging to understand. Notably, studies have shown
that HIV-1 gene transcription is dependent on P-TEFb (Mancebo et al. 1997) and that HDAC
(Bartholomeeusen et al. 2013) or BET inhibition (Bartholomeeusen et al. 2012a) can increase
HIV-1 gene expression. This upregulation results from a secondary effect of HDAC and BET
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inhibitors to release P-TEFb from its inhibitory complex so that it is more available for
transcription elongation.
BET and HDAC inhibitors that have been reported to release P-TEFb from its inhibitory
complex also increase the expression of its negative regulator HEXIM1 (Bartholomeeusen et al.
2012b, 2013). In our study, the BET inhibitor JQ1 transiently decreased the association between
Cyclin T1 and HEXIM1 and induced the expression of HEXIM1. These results suggest that the
HDAC and BET inhibition have different mechanisms of action on adipocyte SOCS regulation,
but results in similar outcomes on gene expression. Moreover, although they are members of the
same family, SOCS3 and CISH likely have very distinct functions, at least in the context of fat
cells. This project underscores the complexity of studying the transcriptional control of genes by
epigenetic modulators.
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Chapter 3. Material and Methods
3.1 Cell culture
Murine 3T3-L1 preadipocytes were grown in Dulbecco’s Modified Eagle’s Media
(DMEM; from Sigma-Aldrich, St. Louis, MO) with 10% bovine calf serum (CALF). Two days
after reaching confluence, cells were induced to differentiate using a standard MDI induction
cocktail of 0.5 mM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, and 1.7 μM insulin in
DMEM containing 10% characterized fetal bovine serum (FBS). HyClone CALF and FBS were
purchased from Thermo Scientific or GE Healthcare Life Sciences (Logan, UT). The medium
was changed every 48 – 72 h during growth, differentiation, and maintenance. When specified,
cells were serum deprived with DMEM containing 0.3% bovine serum albumin (BSA; Cat #:
A6003, Sigma-Aldrich, St. Louis, MO). Otherwise, cells were serum deprived by changing the
media to DMEM containing 1% CALF for 16 to 24 h before treatment with the inhibitors.
Trichostatin A (TSA), nicotinamide (NAM), sodium butyrate and (+)-JQ1 were purchased from
Sigma-Aldrich (St. Louis, MO). The inhibitors CI994 (HDAC1), RGFP966 (HDAC3), LMK235 (HDAC5) and CAY10603 (HDAC6) were purchased from Selleckchem (Houston, TX).
Recombinant murine GH (mGH) was purchased from Dr. A.F. Parlow at the National Hormone
and Peptide Program (NHPP; Torrance, CA).
3.2. Preparation of whole-cell extracts
Cell monolayers were rinsed once with phosphate buffered saline (PBS), then scraped
into non-denaturing IP buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1
mM EDTA, 1% Triton X-100, 0.5% IGEPAL CA-630, protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 μM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10
μM leupeptin, 1mM 1,10-phenanthroline), and a phosphatase inhibitor (0.2 mM sodium
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vanadate). The cell suspension was subjected to a freeze/thaw cycle at -80°C, passed through a
20G needle five times, and clarified by centrifugation at 13,000 x g for 10 min at 4°C.
3.3. Subcellular Fractionation
Mature adipocytes from eight 10-cm culture plates were scraped into 1 mL NHB buffer
per plate. NHB is comprised of 20 mM Tris (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and the same
protease and phosphatase inhibitors used for IP buffer. After adding 10% NP-40 to the cell
suspension using the formula: volume of cell lysate x 0.15/9.85 (0.015% final concentration of
NP-40), it was homogenized on ice using 16 strokes in a Dounce homogenizer. The extract was
centrifuged at 2500 rpm in a Beckman GS-6KR centrifuge with a swinging bucket rotor for 5
min at 4°C. Subsequently, the supernatant containing the cytosolic fraction was transferred to a
fresh tube. The nuclear pellet was washed once with half of the initial volume of NHB buffer and
re-centrifuged at 4°C for 5 min at 2500 rpm in the Beckman GS-6KR centrifuge. The supernatant
was discarded, while the nuclear pellet was resuspended in IP buffer and incubated on ice for 0.5
– 1 h. To break open the nuclei, the nuclear extract was passed through a 20G needle four times;
the extract was then clarified by centrifuging at 13,000 x g for 10 min at 4°C.
3.4. Measurement of protein concentration
Protein content of cell and tissue extracts was quantified using the Bicinchoninic acid
(BCA) assay kit from Sigma-Aldrich (Cat #: BCA1) according to manufacturer’s instructions.
3.5. Gel electrophoresis and immunoblotting
Cell extracts (25-120 μg total protein) were separated on 6, 7.5 or 10% sodium dodecyl
sulfate (SDS) polyacrylamide (PA) gels (acrylamide, Cat #: EC-890, from National Diagnostics,
Atlanta, GA) and transferred to nitrocellulose membranes (Cat #: 162-0115, BioRad, Hercules,
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CA) as previously described (Richard et al. 2013). Results were visualized with horseradish
peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) and enhanced
chemiluminescence (Pierce/Thermo Scientific) as previously described (Richard et al. 2013) or
IRDye-conjugated secondary antibodies (Licor Biosciences, Lincoln, NE) and scanned with the
Odyssey infrared scanner (Licor Biosciences) (Fuller et al. 2014).
3.6. Immunoprecipitation (IP)
Cell extracts (230-500 μg total protein) were incubated with specific antibodies overnight
on a mini-tube rotator at 4°C. Protein A-conjugated agarose (IPA300 Protein A Resin; Cat #: 102003-02) from Repligen or Protein A/G Plus-agarose (Cat #: sc-2003) beads from Santa Cruz
Biotechnology (Dallas, TX) were added to the antibody-epitope mixture. The conjugation
reaction continued for an additional 1 – 2 h at 4°C with rotation. Next, the beads were pelleted by
centrifugation at 13,000 rpm for 3 min at 4°C. The supernatant was removed by aspiration and
the beads were washed 3 times with ice cold 1X IP buffer with protease inhibitors. Between each
wash, the beads were pelleted by centrifugation at 12,000 rpm for 1 min at 4°C and the
supernatant was removed by aspiration. After the final wash, the IP antibody and
immunoprecipitated proteins were eluted from the bead resin into 2X SDS loading buffer (LB)
by boiling the samples for 10 min at 100°C. Samples were flicked multiple times during the heat
step to ensure efficient elution. The samples were briefly centrifuged and the supernatants
analyzed by SDS-PAGE and immunoblotting. A mock sample containing a pool of equal
concentration of all samples and no IP antibody was used as a negative control to ensure there
was no unspecific binding of the beads to protein samples.
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3.7. RT-qPCR
3T3-L1 adipocyte monolayers were harvested in RLT lysis buffer for total RNA
purification using the RNeasy mini kit from Qiagen (Hilden, Germany). RNA concentrations
were quantified by spectrophotometry. cDNA was synthesized by reverse transcription (RT)
using 10 µl of RNA and 10 µl of RT master mix following the protocol of High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster City, CA). The following mouse (m)
genes were examined by RT-qPCR: mCyclophilin a, mNoNo, mSocs3, mCish, mBcl6, mIgf1,
mSocs2, mIgfbp3, mHexim1, using Takara SYBR premix (Takara Bio USA, Mountain View,
CA) and primers purchased from Integrated DNA Technologies (IDT, Skokie, IL). Primers 1 and
2 sequences for each gene are shown in Table 3.2. Assay wells contained 4 ng cDNA in a
reaction volume of 10 l (3 l of cDNA at 1.33 ng/l, plus 7 l of master mix). Analysis was
performed using Applied Biosystems 7900HT Fast Real-Time PCR System and SDS 2.4
software (Applied Biosystems, Foster City, CA). Cyclophilin A and NoNo were used as
endogenous controls.
3.8. Small interfering RNA (siRNA)-mediated knockdown
3T3-L1 mature adipocytes (5-7 days post-MDI) were trypsinized from 6-well plates and
re-plated in 12-well plates at a density of 5.8 x 105 cells/cm2 in antibiotic-free medium (10%
FBS/DMEM). Adipocytes were transfected using the protocol from Dharmacon with
DharmaFECT Duo reagent (Dharmacon; Cat #: T-2010-03) and 50 nM of non-targeting (Cat #:
D-001810-10-50), Hdac4 (Cat #: L-043626-00-0005), Hdac5 (Cat #: L-062182-00-0005), Hdac6
(L-043456-02-0005) siRNA or a combination of two at a time in OptiMEM reduced serum
medium (Thermo Fisher; Cat #: 31985088). Twenty-four hours later, siRNA-containing media
was removed and replaced with antibiotic-free 10% FBS/DMEM. After 24-28 hours, the media
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was replaced by 1% CALF antibiotic-free. On day 2 post-transfection, cells were treated with
vehicle or 5 nM GH for 1 hour. Adipocytes were harvested for RNA in RLT buffer (Qiagen) to
assess knockdown efficiency and effects on STAT5 target gene expression. For knockdown
experiments, Nono was used as the housekeeping gene.
3.9. Chromatin immunoprecipitation (ChIP)
The medium on mature 3T3-L1 adipocytes (7 – 15 days post-MDI) was replaced with 1%
CALF for 16 – 24 h prior to treatment with LMK-235 for 2 hrs, JQ1 for 30 mins, or DMSO
control. Next, the cells were treated with vehicle or GH for 30 min. Six or seven 10-cm plates
per treatment group were used (~4 x 107 cells). ChIP experiments were performed using the
SimpleChIP® Kit (Magnetic Beads) from Cell Signaling Technology (Cat #: 9003S; Danvers,
MA) according to the manufacturer’s instructions. To crosslink DNA and interacting proteins,
cells were incubated at room temperature with 1% formaldehyde (Cat #: 252549) from SigmaAldrich for 10 min. The crosslinking reaction was stopped by the addition of glycine provided in
the kit. The medium was aspirated from adherent adipocytes, and plates were rinsed 2 times with
ice-cold PBS. Cells from each plate were scraped in 1ml ice-cold PBS + 1000 μM PMSF
(phenylmethane sulfonyl fluoride). Cell suspensions from each treatment were combined in a 15ml conical tube and centrifuged as directed. Nuclei preparation, chromatin digestion, and ChIP
assays were performed as indicated in the manufacturer’s instructions. For each ChIP, 8-12 μg of
digested, cross-linked chromatin were incubated with the following amounts of antibodies (Table
3.1), as recommended by the manufacturer: rabbit anti-STAT5A (2 μg), rabbit anti-acetyl histone
H3 (5 μg), rabbit anti-acetyl-histone H4 (1 μg), mouse anti-RNA polymerase II (1 μg), rabbit
anti-phosphoserine2 RNA Pol II (4 μg), rabbit anti-BRD2 (1:50 dilution), non-immune IgG
control antibody rabbit IgG from ChIP kit (2 μg), or mouse IgG from RNA pol II (1 μg). After
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protein digestion and DNA purification using the columns provided by the kit, input and
immunoprecipitated DNA samples were quantitated using the real-time quantitative PCR (qPCR)
in a total volume of 10 μl containing 8 μl reaction master mix and 2 μl DNA (~100 μg/ml), using
an Applied Biosystems 7900HT Fast Real-Time PCR System. We used the qPCR amplification
program specified in the kit instructions with the exception that the initial denaturation step was
performed for 10 min at 95°C. We also added a dissociation curve step at the end of the reaction.
Primers used to amplify different regions of Cish and Socs3 genes are described in table 3.3. A
standard curve prepared with only 2% input samples and 5-fold serial dilutions was used to
access amplification efficiency. Immunoprecipitation efficiency was calculated using the percent
input approach and the following equation: Percent input = 2% x 2(C[T] 2% Input Sample – C[T] IP Sample);
where C[T] = threshold cycle of the PCR reaction.
3.10. Statistical analysis
Data were plotted as mean  standard error (S.E.). The qPCR data were analyzed using either
one-way ANOVA or two-way ANOVA. For ChIP experiments, data were analyzed using twoway ANOVA with Bonferroni’s post hoc test. Differences with p < 0.05 were considered
statistically significant.

28

Table 3.1. List of antibodies used for IPs, ChIPs and Western blots.
Antibody against
Acetyl-Histone H3
Acetyl-Histone H4
Acetylated-Lysine
BRD2 (D89B4)
BRD4
Cyclin T1
HDAC4 (D8T3Q)
HDAC5 (D1J7V)
HDAC6 (D21B10)
HEXIM1
Histone H3
Mouse IgG – Isotype control
Rabbit IgG – Isotype control
RNA polymerase II CTD
repeat YSPTSPS (pS2)
RNA Polymerase II
STAT3(124H6)
STAT5A

Cat number/Company
#06-599; Millipore Sigma
#06-866; Millipore Sigma
#9441; Cell Signaling
#5848; Cell Signaling
#PA5-41550; ThermoFisher
Scientific
#ab184703; Abcam
#15164; Cell Signaling
#20458; Cell Signaling
#7612; Cell Signaling
#ab25388; Abcam
#9715; Cell Signaling
#ab46540; Abcam
#2729; Cell Signaling
ChIP Grade ab5095; Abcam

Host Species/Class
Rabbit polyclonal
Rabbit polyclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit polyclonal

#17-620; Millipore Sigma
#9139; Cell Signaling
E289; ab213219; Abcam

Mouse monoclonal
Mouse monoclonal
Rabbit monoclonal
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Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit polyclonal
Rabbit monoclonal
Mouse monoclonal
Rabbit polyclonal
Rabbit polyclonal

Table 3.2. List of primers used for RT-qPCR.
Gene
Primer 1
5’-GAGAGAACATCAGCGTCCATA-3’
Abhd5 (Cgi-58)
5’-AGTCACATTCGTTGCAGAAGA-3’
Bcl6
5’-CCGCCCAATTTGCTCCA-3’
Cish
5’-TCTTCAGGTCAATAGTCAAGCC-3’
Cyclophilin a (Ppia)
5’-CGAGTGCACCTCATTCCATA-3’
Hdac4
5’-GGATCGTTGTAGAATGCTTGC-3’
Hdac5
5’-GGATGGAGAAATAAAGGACACTGG-3’
Hdac6
5’-CAGCCTCAAACTAGCAACTGTA-3’
Hexim1
5’-ATGCTCTTCAGTTCGTGTGT-3’
Igf1
5’-CATCTGAAGTTCCTCAATGTGC-3’
Igfbp3
5’-CCCACGCCGCGTAGTTCCAG-3’
Lpl
5’-CATCATCAGCATCACCACCA-3’
Nono
5’-CTCGCAACTTCCTTAGCACA-3’
Nrip1
5’-TCTGGGGACTGCCTTTACCAAC-3’
Socs2
5’-GGAAACTTGCTGTGGGTGA-3’
Socs3

Primer 2
5’-CCCACATCTACATCACACCTT-3’
5’-CAGAGATGTGCCTCCATACTG-3’
5’-GCTCCTTTCTCCTTCCATCC-3’
5’-TGCAAACAGCTCGAAGGAGACGC-3’
5’-GCACAAATCCTCTCAACAGACA-3’
5’-CTTCAACTCCGTAGCCATCAC-3’
5’-AGAAGCACCGCATTCAGAG-3’
5’-CTCGATTGCCACCTACTGTC-3’
5’-AGTACATCTCCAGTCTCCTCAG-3’
5’-CCATACTTGTCCACACACCA-3’
5’-AATCTCTTCCCGCGTCTGCTGC-3’
5’-TCTTCAGGTCAATAGTCAAGCC-3’
5’-CTTCCTTTCCCACATAGCAGA-3’
5’-CCTCTGGGTTCTCTTTCACATAGC-3’
5’-GAGATTTCGCTTCGGGACTA-3’

Table 3.3. List of primers used for ChIP-qPCR.
Gene Region
Forward
Cish SBS
5’-CGTCCAGCGATACGATTGGT-3’
Cish TSS
5’-GTTCGCACCACAGCCTTTCAGTCC-3’
Cish Coding
5’-TACCCCTTCCAACTCTGACTGAGC-3’
Socs3 SBS
5’-GCACAGCCTTTCAGTGCAGAG-3’
Socs3 TSS
5’-GCGTACTGGCCGGGTAAATAC-3’
Socs3 Coding
5’-CATTTAGAAGGGAGACAGATGAG-3’

Reverse
5’-CAGGCGTCTAGTGCTTTGGA-3’
5’-TGCCAGGGGTGCGAAGGTCAGG-3’
5’-TTCCCTCCAGGATGTGACTGTG-3’
5’-GTATTTACCCGGCCAGTACGC-3’
5’-GGAGAGACAGCGGTCGTAAG-3’
5’-CATAGGAGAGACAAAGCAGAAC-3’
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Chapter 4. Results
4.1. STAT5 acetylation levels are low in adipocytes
In order to examine modulation of STAT5 acetylation, 3T3-L1 mature adipocytes were
pre-treated for 6 hours with HDAC inhibitors Trichostatin A (TSA), Nicotinamide (NAM) and
Sodium Butyrate (NaBu) at 5 µM, 20 mM and 10 mM, respectively, then treated with vehicle or
5 nM GH for 20 minutes to induce STAT5 phosphorylation and activation. In Fig. 4.1, wholecell extracts were collected, 400 μg of total protein was immunoprecipitated with the pan-acetyl
lysine antibody, and samples were analyzed by Western blot using the STAT5A antibody
overnight. As shown on the left side of Fig. 4.1, a modest amount of acetylated STAT5 was
detected. In the vehicle conditions there was a minor increase in the band intensity with the
presence of HDAC inhibitors, but IgG control band was also lower. In addition, no alterations
were observed in the GH conditions. On the right side of the figure, direct Western blot samples
detection shows a high-intensity band corresponding to STAT5A, confirming the high
expression levels of STAT5A in adipocytes.
In the next experiment, 3T3-L1 mature adipocytes were pre-treated with the same HDAC
inhibitors, then with vehicle or GH for 20 minutes. We then performed the experiment in the
reverse configuration. Whole-cell extracts were immunopreciptated with STAT5A antibody, and
samples were analyzed by Western blot using the pan-acetyl lysine antibody overnight. On the
left side of Fig. 4.2 (immunoprecipitated samples), we observed a band of equivalent size to
STAT5 (approximately 92 kDa). Surprisingly, however, STAT5 acetylation was modestly
decreased by HDAC inhibitors in the presence of GH. We also observed a decrease in band
intensity in the vehicle + inhibitors condition versus vehicle only; however, the IgG band is also
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weaker, suggesting that some of the beads may have been lost. On the right side, the direct
Western blot for pan-acetyl lysine could not detect a band of equivalent molecular weight as
STAT5, even with 100 μg of total protein loaded. Moreover, the inhibitors did not produce the
expected increase in global protein acetylation, but rather seemed to specifically enhance the
intensities of a small number of bands, mostly at high molecular weights. For this reason, we
examined Histone H3 acetylation to verify the efficacy of the inhibitors. Western blot analysis
was performed using 100 μg of whole-cell extracts. As shown in Fig. 4.3, acetyl-histone H3 was
increased by HDAC inhibition, while total H3 levels were unchanged. We also tested whether
serum deprivation the day prior to treatment affected these outcomes. We confirmed that the
inhibitors increased histone H3 acetylation levels and determined that serum deprivation
enhanced this effect.

IP – Pan-Acetyl Lysine (400 µg)
WB – STAT5A

WB (75 µg)
STAT5A

92 kDa
(STAT5A)

Figure 4.1. STAT5 acetylation was not altered by pan-HDAC inhibitors. 3T3-L1 mature
adipocytes were serum-deprived overnight. The following day, cells were pre-treated for 6 hours
(figure caption cont’d.)
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with HDAC inhibitors Trichostatin A (TSA) and Nicotinamide (NAM) at 5 µM and 20 mM
respectively, then treated with 5 nM GH or vehicle (NaHCO3) for 20 minutes. Whole-cell
extracts were isolated, and 400µg of lysates were incubated overnight with pan-acetyl lysine
antibody. STAT5A antibody was used for Western blot analysis. This experiment was
independently repeated on a separate batch of adipocytes.

IP – STAT5A (400 µg)
WB – Pan-Acetyl Lysine

WB (100 µg)
Pan-Acetyl Lysine

92 kDa
(STAT5A)

Figure 4.2. STAT5 acetylation was modestly decreased by pan-HDAC inhibitors. 3T3-L1
mature adipocytes were serum deprived overnight. The next day, cells were pre-treated for 6
hours with HDAC inhibitors Trichostatin A (TSA), Nitotinamide (NAM), and Sodium Butyrate
(NaBu) at 5 µM, 20 mM, and 10 mM, respectively, then treated with 5 nM GH or vehicle
(NaHCO3) for 20 minutes. Whole-cell extracts were isolated, and 400µg of lysates were
incubated overnight with STAT5A antibody. Pan- acetyl-lysine antibody was used for Western
blot analysis. This experiment was independently repeated on a separate batch of adipocytes.
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V

V+I

Non-serum
deprived
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V+I

17 kDa

Ac-H3

17 kDa

Total H3

Figure 4.3. HDAC inhibitors increase Histone H3 acetylation. Mature 3T3-L1 adipocytes were
serum-deprived overnight or kept in media containing 10% bovine serum. Adipocytes were pretreated for 6 hours with HDAC inhibitors Trichostatin A (TSA), Nitotinamide (NAM) and
Sodium Bytarate (NaBu) at 5 µM, 20 mM and 10 mM, respectively. Then, the NaHCO3 vehicle
was added to cells that were harvested 20 minutes later. Western blot analysis was performed
with 100 µg of cell lysates using acetylated histone H3 and total histone H3 antibodies. This
experiment was independently repeated on a separate batch of adipocytes.
In gene expression experiments described later in this Chapter, HDAC inhibitors that
were more specific to individual HDACs could recapitulate the effects of TSA on STAT5 target
genes. Therefore, I repeated the experiments presented in Figs. 4.1 and 4.2, this time pre-treating
adipocytes with 10 μM of the specific HDAC5 inhibitor (LMK-235) for 3 hours, then with
vehicle or GH for 1 hour. In addition, there was a posibility that modulation of STAT5
acetylation would be better detected in isolated nuclear and cytosolic fractions.
Immunoprecipitation was performed using 230 μg of total protein and pan-acetyl lysine
antibody. The resulting blot was probed with the STAT5A antibody. As shown on the left side of
Fig. 4.4, levels of acetylated STAT5 in the nuclear fractions were enhanced in the presence of
GH, while band intensities in the cytosolic samples were considerably lower and were
unchanged with GH treatment. Although LMK-235 did not alter acetylation levels in nuclear or
cytosolic fractions, either in vehicle or GH conditions, the use of cellular fractions allowed us to
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detect higher intensity bands for acetylated STAT5 than we did in whole-cell extracts with the
same antibody combination (Fig. 4.1). This experiment also determined that acetylated STAT5 is
mostly present in the nucleus of adipocytes with GH treatment.

IP – Pan-acetyl Lysine (230 μg)
WB – STAT5A
Nuc

WB (30 μg)
STAT5A

Cyto

Cyto

92 kDa
(STAT5A)

Figure 4.4. STAT5 acetylation is not affected by HDAC5 inhibitor (LMK-235). Mature 3T3-L1
adipocytes were serum-deprived overnight. The next day, adipocytes were pre-treated for 3 hours
with 10 µM of HDAC5 inhibitor LMK-235, then with 5 nM GH or vehicle (NaHCO3) for 1 hour.
Nuclear and cytosolic extracts were isolated, and 230 µg of lysates were incubated overnight
with pan-acetyl lysine antibody. Western blot analysis was performed using STAT5A antibody.
This experiment was independently repeated on a separate batch of adipocytes.
In order to verify the efficacy of LMK-235, we examined if Histone H3 acetylation was
affected by this inhibitor. Adipocytes were pre-treated for 3 hours with increasing doses of
LMK-235, and V or GH was added for one more hour before the cells were harvested. Western
blot analysis shown in Fig. 4.5 demonstrates a dose-dependent increase in Histone H3
acetylation by LMK-235, confirming that LMK-235 modulates acetylation in 3T3-L1
adipocytes. ERK1/2 was used as a loading control.
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Figure 4.5. HDAC5i (LMK-235) increases Histone H3 acetylation. Mature 3T3-L1 adipocytes
were serum-deprived overnight. Adipocytes were pre-treated with increasing doses of LMK-235
for 3 hours. Then, vehicle (NaHCO3) or GH was added to cells 1 hour prior to harvest. Western
blot analysis was performed with 50 µg of whole-cell extracts using acetylated histone H3 and
ERK1/2 antibodies. This experiment was independently repeated on a separate batch of
adipocytes.
To corroborate our observations on GH-induced acetylation of nuclear STAT5, we
repeated cell treatments with the same experimental conditions as in Fig. 4.4, and then used the
reverse configuration of antibodies. Nuclear and cytosolic fractions were isolated.
Immunoprecipitation was performed using 260 μg of total protein and STAT5A antibody
overnight. The resulting blot was probed with the pan-acetyl lysine antibody. As shown on the
left side of Fig. 4.6, low intensity bands corresponding to acetylated STAT5 were detected in the
nuclear but not cytosolic fractions. Direct Western blot analysis shown on the right side of the
figure demonstated that LMK-235 had few effects on cytosolic proteins, except for enhancing
the intensity of a single band similar in size to IgG, both in the presence and absence of GH.
Thus, this experiment confirmed the findings from Fig 4.4, in which STAT5 acetylation levels
are higher in the nucleus than in the cytoplasm of adipocytes. However, band intensities were
considerably lower and LMK-235 modestly increased STAT5 acetylation in the nuclear samples.
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IP – STAT5A (260µg)
WB – Pan-acetyl Lysine
Nuc

Cyto

WB (75µg)
Pan-acetyl Lysine
Cyto

92 kDa
(STAT5A)

50 kDa
(IgG)

Figure 4.6. Nuclear STAT5 acetylation is modestly increased by HDAC5 inhibitor (LMK-235).
Mature 3T3-L1 adipocytes were serum-deprived overnight. The next day, adipocytes were pretreated for 3 hours with 10 µM of HDAC5 inhibitor LMK-235, then with 5 nM GH or vehicle
(NaHCO3) for 1 hour. Nuclear and cytosolic extracts were isolated, and 260 µg of lysates were
incubated overnight with STAT5A antibody. Western blot analysis was performed using panacetyl-lysine antibody. This experiment was independently repeated on a separate batch of
adipocytes.
Given the robust difference in the nuclear band intensity under these conditions (Fig.
4.6), compared to Fig. 4.4, we cannot exclude the possibility that a highly acetylated protein
interacting with STAT5 is being precipitated by the pan-acetyl lysine antibody, and contributing
to a higher intensity band when the membrane is probed for STAT5A. In this case, we would not
be detecting strictly STAT5 acetylation. Another possibility is that in Fig. 4.6, STAT5A antibody
does not pull down acetylated protein very well. As expected, the direct Western of the cytosolic
fractions (30 g protein) shown on the right side of Figure 4.4 reveals very high expression of
STAT5A in adipocytes. We conclude that STAT5 acetylation levels in mature 3T3-L1
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adipocytes are low. In addition, STAT5 acetylation is most likely not accounting for the changes
in GH-mediated induction of STAT5 target genes since HDAC inhibitors had minimal effects on
STAT5 acetylation, despite their ability to modulate GH-induced STAT5 target gene expression.
4.2. GH-induction of STAT5 target genes
Since STAT5 is a transcription factor, we examined the expression of known STAT5
target genes at several time points (0.5 to 48 hours) after a single acute dose of GH. Of the genes
tested, Socs3 and Cish were the most acutely upregulated. Socs3 levels were elevated at 30
minutes and peaked at 1 hour, and returned to near basal levels at 2 hours. Cish expression was
upregulated at 1 hour and remained elevated after 48 hours. As previously reported (Walker,
Nelson, and Frank 2007), Bcl6 was downregulated by GH treatment at all time points. Igf1 and
Socs2 were upregulated at later time points than Cish and Socs3. Igf1 levels were significantly
higher between 4 and 48 hours. Socs2 was upregulated at 2 hours, and levels started to decline
after 12 hours. Igfbp3 was significantly upregulated only after 12 hours and levels continued to
be elevated even at the 48 hour time point (Fig. 4.7).
4.3. HDAC inhibitors increase Socs3 and decrease Cish expression
Given that Socs3 and Cish were the STAT5 target genes most acutely regulated by GH,
we chose to focus on these two genes in the following experiments. In adipocytes treated with
general HDAC inhibitors, TSA or NaBu, the ability of GH to induce Socs3 was increased and the
ability of GH to induce Cish gene expression was decreased under the same conditions (Fig. 4.8).
Notably, the use of NAM, an inhibitor of SIRT deacetylases, had no effect on GH-induced Cish
expression and only a minor effect on Socs3 expression. When all three inhibitors were
combined, we observed an additive effect on Cish suppression, while Socs3 upregulation was
attenuated, compared with TSA or NaBu alone.
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GH (Hours)

Figure 4.7. Regulation of STAT5 target genes by GH. Mature 3T3-L1 adipocytes were treated
with 5 nM GH and harvested at indicated time points. Relative gene expression of Socs3, Cish,
Bcl6, Igfbp3, Igf1 and Socs2 were quantified by RT-qPCR using Cyclophilin a as the reference
gene. Each data point consists of three replicates. This experiment was replicated at least three
times in different batches of cells. Data are presented as means ± S.E. (n=3 per treatment). All
time points are compared to time 0. Statistical significance was determined using one-way
ANOVA. . *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001.
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Figure 4.8. Inhibition of classical HDACs, but not SIRTs, substantially increases the expression
of Socs3 and decreases the expression of Cish. Fully differentiated 3T3-L1 adipocytes were
serum-deprived overnight and then pre-treated for 5 hours with 5 µM Trichostatin A (TSA), 20
mM Nicotinamide (NAM), and/or 10 mM Sodium Butyrate. Next, 5 nM GH or vehicle
(NaHCO3) were added 1 hour before cells were harvested. Gene expression levels were
quantified by RT-qPCR, Cyclophilin a was used as the reference gene. Data are presented as
means ± S.E. (n=3 per treatment). This experiment was replicated at least three times in different
batches of cells. Treatments were normalized to vehicle condition in the absence of inhibitor and
all GH conditions were compared to GH control. Statistical significance was determined using
one-way ANOVA. *P<0.05, **P<0.005, ***P<0.001, ****P<0.0001.
Since TSA and NaBu target several different HDACs, we replicated the previous experiments
using more specific inhibitors. Adipocytes were pretreated with inhibitors of HDACs 1, 3, 5 or 6
for 5 hours, then exposed to GH for 1 hour. As shown in Fig. 4.9, inhibition of either HDAC5 or
6, but not HDAC1 or 3, produced similar effects to those observed with TSA and NaBu.
Of all inhibitors tested, the HDAC5 (LMK-235) and HDAC6 (CAY10603) inhibitors
showed the most potent effects on the GH-induced upregulation of Socs3 and downregulation of
Cish expression. Due to technical difficulties with CAY10603, we performed most of our
subsequent studies using only the HDAC5 inhibitor. To further validate the effects of LMK-235
on Socs3 and Cish expression, adipocytes were pre-treated with LMK-235 for various times (30
minutes to 5 hours) and with GH for one hour prior to harvesting for gene expression analyses.
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As shown in Fig. 4.10A, the effect of LMK-235 is acute, as a 30-minute pretreatment (2 μM)
was sufficient to downregulate Cish to a similar level as longer pretreatment times. For Socs3,
increased pretreatment times resulted in higher levels of GH-induced expression. In addition to
the time course experiment, we tested a variety of doses of this inhibitor. As shown in Fig.
4.10B, a lower dose of LMK-235 (50 nM) was sufficient to reduce GH-induced Cish expression,
while GH-induced Socs3 expression was highly increased at 500 nM. Hence, a ten-fold higher
dose of LMK-235 was required for a similar upregulation of Socs3 than for downregulation of
Cish expression.

Figure 4.9. Pharmacological inhibition of HDAC5 or 6, but not HDAC1 or 3, increases the
expression of Socs3 and decreases the expression of Cish. Fully differentiated 3T3-L1 adipocytes
were serum-deprived with 0.3% BSA DMEM overnight, then pre-treated for 5 hours with the
following specific HDAC inhibitors: 2.5 μM CI994 (HDAC1), 10 μM RGFP966 (HDAC3), 10
μM LMK-235 (HDAC5) and 15 μM CAY10603 (HDAC6). Next, 5 nM GH or an equivalent
volume of vehicle (NaHCO3) were added 1 hour before the cells were harvested. Gene
expression levels were quantified by RT-qPCR and normalized for Cyclophilin a expression.
Data are presented as means ± S.E. (n=3 per treatment). This experiment was replicated three
times in different batches of cells. Treatments were normalized to vehicle condition in the
absence of inhibitor. Statistical significance was determined comparing all GH conditions to GH
control using one-way ANOVA. * p < 0.05 and **** p < 0.0001.
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Figure 4.10. The effect of LMK-235 (HDAC5i) on gene expression is acute, and lower doses
suppress Cish expression than enhance Socs3. (A) Mature adipocytes were pretreated with 2 μM
LMK-235 for 0.5, 2 or 5 hours. Vehicle or 5 nM of GH were added, and cells were harvested 1
hour later. (B) Cells were pretreated for 2 hours with increasing doses of LMK-235. Vehicle or 5
nM GH were added 1 hour before cells were harvested. Gene expression levels were quantified
by RT-qPCR and normalized to Cyclophilin a expression. Data are presented as means ± S.E.
(n=3 per treatment). This experiment was replicated three times in different batches of cells.
Treatments were normalized to vehicle condition in the absence of inhibitor. Statistical
significance was determined using two-way ANOVA. * p < 0.05, *** p < 0.001, **** p <
0.0001.
4.4. STAT5 and HDAC5 do not physically interact in adipocytes
The robust effect of the HDAC inhibitor LMK-235 on STAT5 target genes led us to
hypothesize that HDAC5 was involved in the STAT5 transcriptional complex and possibly being
affected by GH. To test this hypothesis, we performed immunoprecipitation experiments. Mature
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adipocytes were treated with vehicle or GH for either 20 minutes or 1 hour. Whole-cell extracts
were incubated with STAT5A antibody overnight and Western blot analysis was performed
using HDAC5 antibody. As shown on the left side of Fig. 4.11, HDAC5 and STAT5 do not
physically interact in 3T3-L1 adipocytes under the conditions we examined. HDAC5 Western
blot control is shown on the right side of the figure.
IP – STAT5A (400 µg)
WB – HDAC5

WB (120 µg)
HDAC5

140 kDa

HDAC5

Figure 4.11. STAT5 and HDAC5 do not physically interact in 3T3-L1 adipocytes. 3T3-L1
mature adipocytes were serum-deprived overnight then treated with vehicle (NaHCO3) or 5 nM
GH for 20 minutes or 1 hour. Whole-cell extracts were isolated, and 400µg of lysates were
incubated overnight with STAT5A antibody. Next, HDAC5 antibody was used for Western blot
analysis. This experiment was independently repeated on a separate batch of adipocytes.
HDACs possess a nuclear localization signal (NLS) and nuclear export sequence (NES)
(McKinsey, Zhang, and Olson 2001; reviewed in Yang and Grégoire 2005) that allow these
proteins to shift between the nucleus and cytoplasm of the cell. Given STAT5 and HDAC5 can
be present in the cytosol and nucleus of the cell, I next tested if any interaction could be detected
in nuclear extracts. Fig. 4.12 shows no physical interaction even in nuclear extracts. In Western
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blot analysis, an increase in HDAC5 in the nucleus was observed after 1 hour GH treatment. This
observation suggest that HDAC5, like STAT5 migrates to the adipocyte nucleus upon GH
treatment, and while I could not detect an interaction between the two proteins, the possibility
that they interact transiently upon GH treatment cannot be ruled out. Another possibility is that
HDAC5 participates in the GH-signaling pathway independently of STAT5. In addition, as
described later in this chapter, because the HDAC6 inhibitor (CAY10603) also had profound
effects on STAT5 target genes, we performed immunoprecipitation experiments to detect a
possible interaction between HDAC6 and STAT5. However, the HDAC6 antibody did not
perform well, and no interaction was detected (data not shown).

IP – STAT5A (400 µg)
WB – HDAC5

WB (100 µg)
HDAC5

HDAC5

140 kDa

Figure 4.12. STAT5 and HDAC5 do not physically interact in the adipocyte nucleus. 3T3-L1
mature adipocytes were serum-deprived overnight, and then treated with vehicle (NaHCO3) or 5
(figure caption cont’d.)
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nM GH for 20 minutes or 1 hour. Nuclear extracts were isolated and 400 µg of lysates were
incubated overnight with STAT5A antibody. HDAC5 antibody was used for western blot
analysis. This experiment was independently repeated on a separate batch of adipocytes.
4.5. HDACs KD do not recapitulate HDACi effects
In addition to the pharmacological approach, we performed siRNA-mediated knockdown
(KD) of the HDACs targeted by LMK-235. LMK-235 specificity was described by Marek and
colleagues (Marek et al. 2013), and it is shown in table 4.1. HDAC5 IC50 is 4.2 nM, HDAC4
IC50 is 11.9 nM and HDAC6 IC50 is 56 nM. Since these three HDACs were the most affected
by LMK-325, we knocked them down, individually or in combination, and examined the effects
on Socs3 and Cish gene expression. The top section of Fig. 4.13 shows Hdac4, Hdac5 and
Hdac6 gene expression levels, confirming KD efficiency varying between 50-70%. However,
Socs3 and Cish expression were largely unaffected by the knockdowns. HDAC5 protein levels
were also examined, confirming reduced HDAC5 protein levels in KD samples compared to
non-targeting control (data not shown).
Table 4.1. LMK-235 specificity to histone deacetylases (HDACs).
Enzyme
HDAC5
HDAC4
HDAC6
HDAC1
HDAC11
HDAC2
HDAC8

IC50
4.2 nM
11.9 nM
56 nM
320 nM
850 nM
880 nM
1,280 nM

The lack of effect on Socs3 and Cish gene expression with HDAC4, 5 and 6 knockdowns
could be explained by incomplete elimination of HDACs or by compensation through
enhancement of another HDAC when one of them was reduced. The results also raise the
possibility that the effects of HDAC inhibitors on STAT5 target gene expression were not due
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the inhibition of HDACs’ enzymatic activity, but rather to other effects on a protein/proteins in
the STAT5 transcriptional complex.
4.6. HDAC5i (LMK-235) does not affect mRNA stability
To determine if LMK-235 was affecting Socs3 or Cish mRNA stability and potentially
accounting for the observed effects on gene expression, we treated adipocytes with 5 μg/ml
actinomycin D in the presence or absence of LMK-235. Cells were harvested at different time
points (15 to 180 minutes) and relative gene expression was measured. Statistical analysis using
two-way ANOVA demonstrated that LMK-235 had no impact on Socs3 or Cish mRNA stability
(Fig. 4.14), suggesting that the observed effects of the inhibitor were likely due to alterations in
gene transcription.
4.7. BET inhibition has the same effects on Socs3 and Cish gene expression as
pharmacological HDAC inhibition

Since HDAC KDs did not recapitulate the effects of HDAC inhibitors, it is possible that
the inhibitors influence STAT-mediated transcription by interfering with the functions of other
proteins. BET proteins were plausible candidates for this, because they are sensitive to
modulation of acetylation. To investigate whether BET proteins were involved in our observed
changes in Socs3 and Cish gene expression, I acquired the inhibitor thienotriazolodiazepine, JQ1,
which competitively binds to bromodomains of BET proteins and prevents their binding to
acetylated proteins, including histone tails. As shown in Fig. 4.15A, as was the case with LMK235, JQ1 caused dose-dependent downregulation of Cish and upregulation of Socs3. In contrast
to LMK-235, however, the effects of JQ1 decreased with longer pretreatment times, especially
for Socs3 (Fig. 4.15B). Although not significant, in vehicle condition LMK-235 trends to
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increase Cish expression (Fig 4.10), while JQ1 trends to decreased Cish, even in the absence of
GH (Fig. 4.15).
Next, I examined the expression of STAT5 target genes in a GH time course, comparing
DMSO control, LMK-235 or JQ1 alone, or a combination of both. Adipocytes were pretreated
for 30 minutes with JQ1 (1 µM) and/or for 2 hours with LMK-235 (1 μM). As shown in Fig.
4.16, inhibitor pretreatments (Time 0) did not profoundly affect the expression of most STAT5
target genes; however, Bcl6 was modestly affected in the absence of GH. When adipocytes were
treated with GH (0.5 to 6 hours), the inhibitors produced an additive effect on gene expression.
Socs3 upregulation was even higher in the presence of LMK-235 and JQ1, while Cish
suppression was even greater in the presence of both inhibitors. The effects seemed to also be
additive for Igf1, which showed a suppression pattern similar to that of Cish. For Socs2, LMK235 alone upregulated gene expression at 6 h, while JQ1 alone or in combination with LMK-235
suppressed its expression.
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Figure 4.13. HDAC4, 5, or 6 knockdowns did not recapitulate the effects of HDAC inhibitors. Fully differentiated 3T3-L1 adipocytes
were transfected with 50 nM non-targeting (NT) siRNA or HDAC4, 5, or 6 siRNA, or a combination of 2 at a time. siRNA-containing
media was removed 24 hours later and replaced with 10% FBS. After 48 hours, FBS was replaced by 1% CALF. The following day,
(figure caption cont’d.)
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cells were treated with vehicle (10 μM NaHCO3) or 5 nM murine growth hormone (GH) for 1
hour. RT-qPCR analysis was performed using Nono as the reference gene. Knockdown of
Hdac4, 5, and/or 6 was confirmed by examining their gene expression levels. Expression levels
of the target genes Socs3 and Cish were also analyzed. Data are presented as means ± S.E. (n=3
per treatment). This experiment was replicated twice in different batches of cells. Treatments
were normalized to vehicle condition in the absence of inhibitor. Statistical significance was
determined comparing all GH conditions to GH control using one-way ANOVA. * p < 0.05, ** p
< 0.005, *** p < 0.001, **** p < 0.0001.

Figure 4.14. LMK-235 has no effect on Socs3 or Cish mRNA stability. Fully differentiated
adipocytes were treated with 2 μM LMK-235 followed by 5 μg/ml actinomycin D. Cells were
harvested at the indicated time points. Gene expression levels were quantified by RT-qPCR,
Cyclophilin a was used as the reference gene. Data are presented as means ± S.E. (n=3 per
treatment). This experiment was replicated at least three times in different batches of cells.
Statistical significance was calculated using two-way ANOVA, there was no difference between
treatments.
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Figure 4.15. JQ1 upregulates Socs3 and downregulates Cish in a similar manner as LMK-235.
(A) Mature 3T3-L1 adipocytes were pretreated for 30 minutes with JQ1 at different
concentrations. Vehicle or 5 nM of GH were added 1 hour before the cells were harvested. (B)
Mature adipocytes were pretreated with 2 μM JQ1 for indicated times, and vehicle or 5 nM of
GH were added 1 hour before the cells were harvested. Gene expression levels were quantified
by RT-qPCR. Cyclophilin a was used as the reference gene. Data are presented as means ± S.E.
(n=3 per treatment). This experiment was replicated three times in different batches of cells.
Treatments were normalized to vehicle condition in the absence of inhibitor. Statistical
significance was determined using two-way ANOVA. *P<0.05, **P<0.005, ***P<0.001,
****P<0.0001.
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4.8. BRD2 and RNA Pol II binding to Socs3 and Cish correlate with changes in gene
expression

To better investigate DNA-protein interactions in a site-specific manner, we performed
chromatin immunoprecipitation (ChIP) analysis. Fig. 4.17A represents the schematics of the
three target regions that were amplified by qPCR, one region containing STAT binding sites,
another containing the transcription start site (TSS), and the last one within the coding region of
Cish. Fig. 4.17B corresponds to the equivalent regions of Socs3. As shown in Figures 4.17C and
4.17D, STAT5A binding to STAT binding sites increased with GH treatment, and this increase
was even greater in the presence of LMK-235 at both Socs3 and Cish promoters. JQ1 slightly
increased STAT5A binding in the vehicle/basal condition and had no significant effects in the
GH condition. The similarities in STAT5A binding to the Socs3 or Cish promoters suggest that
the opposite effects on gene expression by HDAC or BET inhibition are not due to significant
differences in STAT5A binding.
Since STAT3 can also be activated in adipocytes and Socs3 is a well-known STAT3
target gene (L. Zhang et al. 2006), I also examined its binding to Cish and Socs3 promoters. As
shown in Fig. 4.17E no significant changes with GH or inhibitors were detected on the Cish
STAT binding site. At Socs3, only JQ1 substantially increased STAT3 binding. Moreover, GH
treatment seems to decrease STAT3 binding, perhaps permitting more STAT5 binding (Fig.
4.17F).
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Figure 4.16. Effects of LMK-235 and JQ1 on STAT5 target genes are greatest when combined.
Mature adipocytes were pre-treated for 2 hours with 1 μM LMK-235, for 30 min with 1 μM JQ1
or a combination of both. DMSO was used as a control. Subsequently, the cells were treated with
5 nM GH and harvested at the indicated time points. Relative gene expression of Socs3, Cish
(figure caption cont’d.)
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Socs2, Igf1 and Bcl6 were quantified by RT-qPCR using Cyclophilin a as the reference gene.
Data are presented as means ± S.E. (n=3 per treatment). This experiment was replicated two
times in different batches of cells.
Next, we assessed changes in BET protein binding to Cish and Socs3 promoters. The
binding of BRD4, the most thoroughly characterized BET protein, was lower than that of BRD2,
and binding levels were comparable to IgG control (Fig. 4.18A-D). In addition, results with
BRD4 were inconsistent. In one experiment, BRD4 appeared to be recruited to the Cish TSS by
GH and its binding was decreased by JQ1 (Fig. 4.18A). However, when this experiment was
repeated, these effects of GH and JQ1 on BRD4 binding to the Cish promoter were not observed
(Fig. 4.18C). BRD2, on the other hand, was consistently recruited by GH to the Cish TSS in
three independent experiments. These results are in accordance with previous studies that
revealed BRD2 as the BET protein involved in STAT5 transcriptional activity (Liu et al. 2014a;
Pinz et al. 2015a). The recruitment of BRD2 to the Cish promoter was attenuated by LMK-235
in the GH condition and by JQ1 in both conditions (Fig. 4.18E). Conversely, neither BRD2 nor
BRD4 were recruited to Socs3 TSS by GH. However, the presence of LMK-235 increased BRD2
binding in both vehicle and GH conditions (Fig. 4.18F). These results suggest that BRD2 is
necessary for GH activation of Cish but not Socs3.
As expected, total RNA polymerase II binding to Cish and Socs3 TSS was increased by
GH treatment. In the presence of LMK-235, RNA Pol II binding to Cish TSS was decreased only
in the GH condition (Fig. 4.19A), which is consistent with the gene expression pattern observed
with LMK-235 (Fig. 4.10). Moreover, LMK-235 enhanced RNA Pol II binding to the Socs3 TSS
in both the V and GH conditions. JQ1 increased Pol II binding to the Socs3 TSS only in the
vehicle condition and slightly decreased its binding in the presence of GH (Fig. 4.19B). At the
same time, JQ1 decreased Pol II binding to the Cish TSS in both V and GH conditions, which is
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also consistent with the observed changes in gene expression, since JQ1 always decreases Cish
expression in the presence or absence of GH (Fig. 4.15). The binding of Pol II phosphorylated at
Ser2, a marker of RNA elongation, to the coding regions of Socs3 and Cish was increased with
GH. While association of this activated Pol II to the coding region of Cish was suppressed by the
inhibitors (Fig. 4.19C), the increase was even greater for Socs3 when HDACs or BETs were
inhibited (Fig. 4.19D). These results indicate that HDAC or BET inhibitors decrease RNA Pol II
recruitment to the Cish promoter and increase Socs3 transcription elongation.
Because BET proteins bind to acetylated histones, we assessed acetylated H3 and H4
levels at the TSS and coding regions of both Cish and Socs3. For acetyl-histone H3, the
inhibitors had very similar effects in Cish and Socs3. However, GH produced a significant
increase in binding only at the Cish TSS. Interestingly, in both genes, LMK-235 reduced
acetylated H3 binding at the TSS while enhancing binding in the coding region. Compared to
acetylated H3, acetyl-histone H4 levels differed more between Cish and Socs3. Yet, we saw the
same increase with GH and reduction with LMK-235 at the Cish TSS. Moreover, acetylation
levels at the Cish TSS were much higher for all conditions, when compared to Socs3. These
findings support the hypothesis that Cish transcription depends on BRD2 and therefore higher
acetylation levels at TSS. LMK-235 decreases acetylation levels at the Cish TSS while
increasing them in the coding region. These shifts result in displacement of BRD2 from the TSS.
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Figure 4.17. Changes in STAT5 and 3 binding to Socs3 and Cish promoters do not correlate
with changes in gene expression. Schematics of Cish (A) and Socs3 (B) regions that were
amplified by qPCR, including STAT binding site, transcription start site (TSS) and coding region
of the genes. (C-F). Mature adipocytes were pre-treated with 2 μM LMK-235 for 2 hours, or 2
μM JQ1 for 30 minutes. DMSO was used as a control. Next, cells were treated with vehicle (V;
NaHCO3) or 5 nM GH for 35 min. Chromatin was cross-linked using formaldehyde, and nuclear
extracts were subjected to ChIP using STAT5A and STAT3 antibodies. The amount of bound
DNA was measured by qPCR at the STAT binding site and percent input was calculated. This
experiment was replicated three times in different batches of cells. Statistical significance was
calculated using two-way ANOVA with Bonferroni’s post hoc test. * denotes significance
between DMSO and inhibitor treatments within either the V or GH condition. # denotes
significance between V and GH for each control and inhibitor treatment. * p < 0.05, ** p <
0.005, *** p < 0.001, **** p < 0.0001; # p <0.05, ### p < 0.005, ### p <0.001, #### p < 0.0001.
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Figure 4.18. BRD2 is necessary for GH induction of Cish but not Socs3. Mature adipocytes were
pre-treated with 2 μM LMK-235 for 2 hours, or 2 μM JQ1 for 30 minutes. DMSO was used as a
control. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 min. Chromatin
was cross-linked using formaldehyde, and nuclear extracts were subjected to ChIP using BRD2
and BRD4 antibodies. The amount of bound DNA was measured by qPCR at the TSS and
percent input was calculated. This experiment was replicated three times in different batches of
cells. Statistical significance was calculated using two-way ANOVA with Bonferroni’s post hoc
test. * denotes significance between DMSO and inhibitor treatments within either the V or GH
condition. # denotes significance between V and GH for each control and inhibitor treatment. * p
< 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001; # p <0.05, ### p < 0.005, ### p <0.001, #### p
< 0.0001.
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Figure 4.19. Changes in RNA Polymerase II binding to Socs3 and Cish reflect the fluctuations in
gene expression. Mature adipocytes were pre-treated with 2 μM LMK-235 for 2 hours, or 2 μM
JQ1 for 30 minutes. DMSO was used as a control. Next, cells were treated with vehicle (V;
NaHCO3) or 5 nM GH for 35 min. Chromatin was cross-linked using formaldehyde, and nuclear
extracts were subjected to ChIP using RNA Pol II and RNA Pol IIpS2 antibodies. The amount of
bound DNA was measured by qPCR and percent input was calculated. This experiment was
replicated three times in different batches of cells. Statistical significance was calculated using
two-way ANOVA with Bonferroni’s post hoc test. * denotes significance between DMSO and
inhibitor treatments within either the V or GH condition. # denotes significance between V and
GH for each control and inhibitor treatment. * p < 0.05, ** p < 0.005, *** p < 0.001, **** p <
0.0001; # p <0.05, ### p < 0.005, ### p <0.001, #### p < 0.0001.
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Figure 4.20. Effects of inhibitors on Histone H3 acetylation were very similar for Socs3 and
Cish. Mature adipocytes were pre-treated with DMSO for 2 hours, 2 μM LMK-235 for 2 hours,
or 2 μM JQ1 for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for
35 min. Chromatin was cross-linked using formaldehyde, and nuclear extracts were subjected to
ChIP using anti-acetyl histone H3. The amount of bound DNA to Socs3 and Cish STAT binding
site, transcription start site (TSS), and coding region was measured by qPCR and percent input
was calculated. This experiment was replicated three times in different batches of cells.
(figure caption cont’d.)
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Statistical significance was calculated using two-way ANOVA with Bonferroni’s post hoc test. *
denotes significance between DMSO and inhibitor treatments within either the V or GH
condition. # denotes significance between V and GH for each control and inhibitor treatment. * p
< 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001; # p <0.05, ### p < 0.005, ### p <0.001,
#### p < 0.0001.
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Figure 4.21. Acetyl Histone 4 levels were higher at the TSS of Cish than of Socs3. On the day
(figure caption cont’d.)
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before the experiment, mature adipocytes were fed with 1% CALF. On the day of the
experiment, cells were pre-treated with DMSO for 2 hours, 2 μM LMK-235 for 2 hours, or 2 μM
JQ1 for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 min.
Chromatin was cross-linked using formaldehyde, and nuclear extracts were subjected to ChIP
using anti-acetyl histone H4. The amounts of bound DNA to Socs3 and Cish STAT binding sites,
transcription start sites and coding regions were measured by qPCR and percent input was
calculated. This experiment was replicated three times in different batches of cells. Statistical
significance was calculated using two-way ANOVA with Bonferroni’s post hoc test. * denotes
significance between DMSO and inhibitor treatments within either the V or GH condition. #
denotes significance between V and GH for each control and inhibitor treatment. * p < 0.05, ** p
< 0.005, *** p < 0.001, **** p < 0.0001; # p <0.05, ### p < 0.005, ### p <0.001, #### p <
0.0001.
Rabbit IgG antibody was used as the negative control on ChIP experiments. IgG
binding levels at Socs3 and Cish STAT binding site, transcription start site (TSS) and coding
regions ranged between 0.02 and 0.1% input (Fig. 4.22).
4.9. JQ1 disrupts HEXIM1 and Cyclin T1 interaction
Displacement of BRD2 from the Cish promoter upon HDAC or BET inhibition
explains why GH induction of Cish was being negatively affected by these inhibitors. The
upregulation of Socs3 by HDAC inhibition is probably due an increase in chromatin
accessibility. On the other hand, the upregulation of Socs3 by JQ1 is more challenging to explain
because BET proteins are positively correlated with transcription. Extensive work done in HIV
transcription has shed light on the mechanism by which JQ1 could upregulate some genes. It is
possible that the effects of JQ1 on Socs3 may not involve BET proteins at all. As previously
described here, JQ1 and other inhibitors were reported to affect the interaction between the
positive elongation factor-b (P-TEFb) and its negative regulator HEXIM1, leaving P-TEFb more
available for transcription elongation. As a consequence, HEXIM1 is upregulated at the mRNA
and protein levels to restore the equilibrium between active and inactive P-TEFb.
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Cish

Socs3

Figure 4.22. Rabbit IgG levels bound to the three amplified region of Cish and Socs3. On the
day before the experiment, mature adipocytes were fed with 1% CALF. On the day of the
experiment, cells were pre-treated with DMSO for 2 hours, 2 μM LMK-235 for 2 hours, or 2 μM
JQ1 for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 min.
Chromatin was cross-linked using formaldehyde, and nuclear extracts were subjected to ChIP
using rabbit IgG antibody. The amounts of bound DNA to Socs3 and Cish STAT binding sites,
transcription start sites and coding regions were measured by qPCR and percent input was
(figure caption cont’d.)
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calculated. This experiment was replicated three times in different batches of cells. Statistical
significance was calculated using two-way ANOVA with Bonferroni’s post hoc test. * denotes
significance between DMSO and inhibitor treatments within either the V or GH condition. #
denotes significance between V and GH for each control and inhibitor treatment. * p < 0.05, ** p
< 0.005, *** p < 0.001, **** p < 0.0001; # p <0.05, ### p < 0.005, ### p <0.001, #### p <
0.0001.
To investigate if inhibitors were affecting the interaction between the regulatory subunit
of P-TEFb (Cyclin T1) and HEXIM1, adipocytes were treated with LMK-235 or JQ1 for 2, 6, or
24 hours. Whole-cell lysates were immunoprecipitated with Cyclin T1 antibody, and Western
blot analysis was performed in the following day. In Fig. 4.23, the fold-change values for BRD2
and HEXIM1 are indicated under the blot images. For the 2-hour JQ1 treatment, the interaction
between Cyclin T1 and HEXIM1 was reduced, while interaction with BRD2 was increased. As
the interaction with HEXIM1 increased over time, the interaction with BRD2 decreased. With
LMK-235 treatment, the interaction between Cyclin T1 and HEXIM1 was not reduced.
However, the interaction with BRD2 decreased over time, probably because LMK-235 treatment
decreased BRD2 expression as shown later in Fig. 4.25.
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Figure 4.23. JQ1 transiently reduces HEXIM1-Cyclin T1 interaction. Mature 3T3-L1 adipocytes
were treated with 2 μM JQ1 or 2 μM LMK-235 for the indicated times. Control (CTL) cells were
(figure caption cont’d.)
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untreated. Whole-cell extracts were collected in IP buffer and 300 μg of total protein was
incubated with anti-Cyclin T1 antibody overnight. Interacting HEXIM1 and BRD2 were detected
by Western blot. The mock sample was composed of a pool of all samples without any antibody.
Band intensities were quantified and Cyclin T1 was used as a loading control to calculate foldchange values, which are shown below the BRD2 and HEXIM1 immunoblots.
I also examined whether the HDAC inhibitors or JQ1 that upregulated Socs3 and
downregulated Cish had any effects on Hexim1 expression. A time course experiment showed
that only JQ1 significantly upregulated Hexim1, while LMK-235 and CAY10603 (HDAC6i) had
no impact on Hexim1 gene expression. The upregulation by JQ1 is noticeable at 2 hour, peaks at
6 hours, and begins to wane at 24 hours, while remaining significantly higher than in DMSO
control or HDAC inhibition conditions. A combination of JQ1 with LMK-235 did not further
upregulate Hexim1 (Fig. 4.24). As previously shown, LMK-235, CAY10603, and JQ1 increased
GH induction of Socs3 while decreasing Cish induction.
Subsequently, I measured HEXIM1 protein levels at the same time points and
observed a progressive accumulation of HEXIM1 when the cells were treated with JQ1 but not
LMK-235. LMK-235 modestly decreased HEXIM1 protein levels at 24 hours treatment.
Unexpectedly, JQ1 and LMK-235 had profound and opposite effects on BRD2 protein levels.
While JQ1 upregulated BRD2, LMK-235 drastically decreased BRD2 protein levels.
Quantification of BRD2 and HEXIM1 was performed using the regulatory part of P-TEFb,
(Cyclin T1) as a control; results are expressed as fold-change over control condition and shown
below the Western blot images (Fig. 4.25).
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Figure 4.24. JQ1 upregulates Hexim1. Fully differentiated adipocytes were treated with 2 μM
LMK-235, 10 μM CAY10603, or 2μM JQ1, or a combination of LMK-235 and JQ1. Next, 5 nM
GH was added and cells were harvested at the indicated time points. Gene expression levels were
quantified by RT-qPCR, using Nono as the reference gene. Data are presented as means ± S.E.
(n=3 per treatment). This experiment was replicated twice in different batches of cells. Statistical
significance was calculated using two-way ANOVA with Bonferroni’s post hoc test. * denotes
#
significance between DMSO and inhibitor treatments. denotes significance between time
#
###
###
points. * p < 0.05, ** p < 0.005, *** p < 0.001, **** p < 0.0001; p <0.05,
p < 0.005, p
####
<0.001,
p < 0.0001.
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Figure 4.25. JQ1 upregulates HEXIM1 and BRD2, while LMK-235 robustly downregulates
BRD2 expression. Mature 3T3-L1 adipocytes were treated with 2 μM JQ1 or 2 μM LMK-235
for the indicated times. Control (CTL) cells were untreated. Whole-cell extracts were collected in
IP buffer and 25 μg of protein was used for gel electrophoresis. HEXIM1, BRD2, and Cyclin T1
protein levels were detected by Western blot. Band intensities were quantified and Cyclin T1 was
used as a loading control to calculate fold-change. Statistical significance was calculated using
one-way ANOVA . * denotes significance between CTL and respective treatments.
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Chapter 5. Discussion
Our previous work demonstrated that STAT5 interacts with the pyruvate dehydrogenase
complex (PDC) in the adipocyte nucleus in a GH-dependent manner (Richard, Hang, and
Stephens 2017). This interaction led us to hypothesize that PDC could be generating acetyl-CoA
for acetylation of STAT5 or histones, or affecting the function of other proteins in the STAT5
transcriptional complex. It is important to point out that we had not measured the production or
fate of acetyl-CoA derived specifically from PDC, therefore, the GH-mediated STAT5-PDC
interaction we observed only provided the suggestion that acetylation may be important for
STAT5 transcriptional activity in adipocytes. The initial focus of this research was to effectively
measure STAT5 acetylation in mature 3T3-L1 adipocytes. The role of acetylation in STAT5
transcriptional activity is controversial in the literature. STAT5B acetylation was detected by
mass spectrometry at K359, K694 and K701 (corresponding to K359, K689 and K696 of
STAT5A) by Ma et al, who found that mutations of K359 and K694 reduced prolactin-induced
STAT5 activity measured by luciferase assay. In addition, mutations of K694 or K701, which are
close to the SH2 domain, impaired dimerization of STAT5B, suggesting a positive role of
acetylation in STAT5 downstream transcriptional activity (Ma et al. 2010). In another study,
STAT5A SUMOylation competed with acetylation at K696 and decreased STAT5A
transcriptional activity (Van Nguyen et al. 2012).
Conversely, studies using HDAC inhibitors have shown that increasing acetylation levels
in the cell suppresses STAT-dependent gene activation. In macrophages, the HDAC inhibitor
TSA repressed STAT5-mediated transcription, but had no effects on STAT5 phosphorylation or
binding activity (Sebastián et al. 2008). Similarly, activation of STAT5 target genes in the IL-3dependent pro-B cell line Ba/F3 was blocked by HDAC inhibitors, while mutations in STAT5
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lysine residues, had no effects on STAT5 transcription activity (Rascle, Johnston, and Amati
2003; Pinz et al. 2015). Comparable results were observed in the activation of genes dependent
on STATs 1 or 2 (Nusinzon and Horvath 2003; Sakamoto, Potla, and Larner 2004) and STAT3
(Catania et al. 2006). However, a study performed in human colorectal cancer cells demonstrated
that TSA induced the expression of two STAT3 target genes, SOCS1 and SOCS3 (Xiong et al.
2012).
STAT5 is highly expressed in mature 3T3-L1 adipocytes and in adipocytes in vivo. As
shown in Fig. 4.1, 75 μg of total protein is sufficient to observe robust STAT5A expression in
mature 3T3-L1 adipocytes. However, when 400 μg of total protein was immunoprecipitated with
pan-acetyl lysine antibody and the membrane was probed for STAT5A (Fig. 4.1) or the inverse
configuration of antibodies (Fig. 4.2) under the same experimental conditions, only low-intensity
bands corresponding to STAT5A size are observed. In addition, pan-HDAC inhibitors had little
effects on STAT5 acetylation. Western blot analysis examining histone H3 acetylation confirmed
the efficacy of inhibitors (Fig. 4.3). When adipocytes were treated with HDAC5 inhibitor (LMK235) and nuclear and cytosolic fractions were isolated, higher intensity bands were observed in
the nuclear fractions treated with GH. However, LMK-235 had no effects on STAT5 acetylation
(Fig 4.4). Western blot analysis probing for acetyl-histone H3 demonstrated that LMK-235
increased histone acetylation in a dose-dependent manner (Fig. 4.5). The reverse configuration of
antibodies employed in figure 4.4, detected far lighter bands in the nuclear fractions (Fig 4.6). A
possible explanation is that highly acetylated protein/proteins interact with STAT5 in the nucleus
upon GH activation, and this complex is immunoprecipitated by pan-acetyl lysine antibody,
contributing to the high-intensity bands observed when the membrane is probed for STAT5A
(Fig. 4.4). When samples are immunoprecipitated with STAT5A antibody, these acetylated
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proteins are not enriched in the STAT5A complex, explaining the lower intensity bands observed
in figure 4.6. Thus, we believe this antibody configuration is a more faithful representation of
STAT5 acetylation levels in 3T3-L1 adipocytes, which were very low, compared to the
expression of total STAT5A protein.
In addition, the HDAC inhibitors TSA, NaBu, NAM or LMK-235 had little or no impact
on STAT5 acetylation (Figs. 4.1, 4.2, 4.4 and 4.6), even though they substantially increased the
acetylation levels of a small number of bands, mostly at high molecular weights (Fig. 4.2) and
Histone H3 (Figs. 4.3 and 4.5) in adipocytes. It is important to point out that the methods utilized
in this work measured changes in total STAT5 acetylation and we cannot exclude the possibility
that acetylation of a single STAT5 lysine residue could be affected by HDAC inhibitors and
escape detection by our methods. We also carry out immunoprecipitation experiments with an
acetylated-STAT5B antibody, however, the antibody did not perform well (data not shown) and
we were unable to find a better acetylated-STAT5 antibody. To specifically assess the
contribution of each lysine residue, we would have to use more specific antibodies or perform
mutations on each potential lysine residue that could be acetylated in STAT5. However, as
previous studies mentioned above, mutations in lysine residues had no impact on STAT5
activation measured by luciferase assay or on the induction of STAT5 target genes (Pinz et al.
2015). Based on these studies and our own observations, we concluded that the effects of HDAC
inhibitors on STAT5 target genes are largely independent of STAT5 acetylation. Thus, we
decided to not further investigate STAT5 acetylation in adipocytes.
STAT5 can be activated by GH or PRL in adipocytes (Zvonic et al. 2003; Fleenor,
Arumugam, and Freemark 2006). Thus, to validate the induction or repression of known STAT5
target genes, a GH time course was performed. Our results were consistent with published data

68

from other groups. Indeed, Socs3 has been reported to be rapidly and transiently upregulated by
GH in 3T3-F222A fibroblasts, in which levels peaked after 30 min GH exposure and returned to
basal levels after 2 hours. In the same study, Socs1 was activated to a lesser extent but had a very
similar induction pattern to that of Socs3 (Adams et al. 1998). As shown in Fig. 4.7, we observed
the same acute and transient induction of Socs3 by GH in 3T3-L1 adipocytes (Socs1 induction
was not measured in our study). Adams et al. also found that Socs2 expression was only induced
at later time points, starting at 2 hours and peaking at 4 hours treatment, while maximal induction
of Cish was observed at 1 hour GH-treatment, with sustained activation at later time points
(Adams et al. 1998). Very similar induction patterns of Socs genes were observed in rat
hepatocytes treated with GH (Tollet-Egnell et al. 1999). As shown in Figure 4.7, our analysis of
GH-induced gene expression changes in adipocytes therefore closely mirrors observations from
other cell types.
STAT5 is thought to mediate the growth-promoting effects of GH in the liver through
upregulation of IGF-1. A study in hepatocytes showed STAT5 binding to a distal DNA region
and induction of Igf1 expression with 8 hours GH treatment (Y. Wang and Jiang 2005). In
adipocytes, a 4-hour exposure to GH upregulated Igf1 (Fleenor, Arumugam, and Freemark
2006). Our study confirms Igf1 induction by GH in 3T3-L1 adipocytes at 4 hours, with sustained
high levels until the last time point at 48 hours. Induction of Igfbp3 by GH has been described in
rat beta-cells (De et al. 1995) and in the adipose tissue of acromegaly patients (Hochberg et al.
2015). In the current study, expression levels in adipocytes were significantly increased at 12
hours, and even more elevated after 48 hours (Fig. 4.7). Since IGFBP-3 is an IGF carrier in the
circulation and Igf1 expression was increased by GH, it is reasonable that Igfbp3 is upregulated
at later time points compared to Igf1. Despite GH induction, we did not find evidence to show
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that Igfbp3 is a STAT5 target gene. Thus, Igfbp3 might be induced by another GH-induced
signaling pathway that does not involve STAT5. Additionally, contrary to genes that are
positively regulated by GH-STAT5 signaling, Bcl6 has been reported to be negatively regulated
by STAT5 in 3T3-F442A adipocytes (G. Lin et al. 2014) and in B-lymphoma cells (Walker,
Nelson, and Frank 2007). Our results confirm a rapid and sustained repression of bcl6 expression
by GH in 3T3-L1 adipocytes (Fig. 4.7).
Socs3 and Cish were the STAT5 target genes most acutely upregulated by GH treatment,
and treatment of adipocytes with some HDAC inhibitors had profound and opposite effects on
GH induction of Socs3 and Cish. Among the inhibitors tested, the general HDAC inhibitors,
TSA and NaBu (Fig. 4.8) and the more specific inhibitors LMK-235 (HDAC5i) and CAY10603
(HDAC6i) (Fig. 4.9) were able to modulate the ability of GH to induce Socs3 and Cish
expression. Surprisingly, treatment of adipocytes with 20 mM of the SIRT inhibitor NAM had no
effects on GH-induction of Cish and minimal effects on Socs3 expression, despite the fact that
SIRT1 had been reported to interact with STAT5 and that 10 mM of NAM was shown to affect
GH induction of Igf1 in hepatocytes (Yamamoto et al. 2013). Moreover, the HDAC3 inhibitor
(RGFP966) had no effects on Socs3 and Cish gene expression even though STAT5 was
previously shown to interact with HDAC3 in Ba/F3 cells (Nanou et al. 2017).
The potent opposite effects of HDAC5i (LMK-235) on Socs3 and Cish gene expression
(Fig. 4.10), led us to consider a possible physical interaction between STAT5 and HDAC5.
However, immunoprecipitation experiments failed to detect any interaction between STAT5 and
HDAC5 (Figs. 4.11 and 4.12) or between STAT5 and HDAC6 (data not shown). However, 1
hour GH treatment increased HDAC5 translocation to the adipocyte nucleus (Fig. 4.12). It has
been known for several years that phosphorylation is the principal mechanism regulating nucleo-
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cytoplasmic shutting of class IIa HDACs (McKinsey, Zhang, and Olson 2001; Kao et al. 2001).
Nuclear export of HDAC5 was shown to involve calcium/calmodulin-dependent kinase (CaMK)mediated phosphorylation at Ser259 and Ser498 (Jia-YiWei et al. 2015; McKinsey, Zhang, and
Olson 2001), while nuclear retention is mediated by cAMP-activated protein kinase A (PKA)
phosphorylation at Ser280 (Ha et al. 2010). Moreover, a study demonstrated that hormonedependent regulation of HDAC4 interferes with its cellular localization (B. Wang et al. 2011).
Given that GH triggers other pathways besides JAK-STAT signaling (reviewed in Chia 2014), it
is possible that HDAC5 translocation to the adipocyte nucleus is mediated by a different GH
signaling pathway that does not involve a physical interaction with STAT5.
In addition to inhibiting HDAC5, LMK-235 can also affect other HDACs (Table 4.1),
particularly the other class IIa member, HDAC4, and the class IIb member HDAC6. A possible
role for HDAC6 in regulating STAT5-mediated transcription is supported by the effects of the
HDAC6 inhibitor (CAY10603) on Socs3 and Cish gene expression (Fig. 4.9). HDAC4 is very
similar to HDAC5, and we could not obtain a more selective HDAC4 inhibitor. As an alternative
to pharmacological inhibition, we used siRNA-mediated knockdown to individually
downregulate HDAC4, HDAC5 or HDAC6. However, this approach did not recapitulate the
effects of inhibitors on STAT5-mediated transcription, even when two HDACs were knocked
down in combination (Fig. 4.13). These observations could be due to residual levels of protein
following siRNA-knockdown or may result from compensation by other HDACs when one or
two of them are knocked down. Another explanation is that enzymatic inhibition of HDACs and
depletion by siRNA knockdown might generate different cellular effects, as suggested by the
results of a study comparing HDACi treatment and HDAC class I knockdowns showing less than
4% overlap among the genes altered by these two modes of inhibition (Dejligbjerg et al. 2008).
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Thus, HDAC inhibitors can have alternative effects that are independent from inhibition
of HDAC enzymatic activity. In neuroblastoma cell lines, the class I HDAC inhibitor sodium
valproate (VPA) promoted cell death by down regulation of survivin, an anti-apoptotic protein,
through activation of the AKT pathway, while HDAC knockdown had no effects on survival
(Shah et al. 2013). This concept is reinforced by evidence that Class IIa HDACs, which include
HDACs 4 and 5, have weak catalytic activity and are dependent on complexes that include other
HDACs, such as HDAC3 (Fischle et al. 2002). Additionally, Pinz et al demonstrated that only
the HDAC inhibitors that induce histone hyperacetylation influenced STAT5-mediated
transcription. In that study, the inhibitors that had no effects on gene expression, MGCD0103
and MS-275 (Entinostat), were benzamides (Pinz et al. 2015). In the current study LMK-235
induced histone hyperacetylation (Fig. 4.5), but we have not tested the other inhibitors
individually. Curiously, the inhibitors that had the most profound effects on STAT5 target genes
(TSA, LMK-235 and CAY10603) are all hydroxamic acids, while CI994 (HDAC1i) and
RGFP966 (HDAC3i) are benzamides. Although we have not determined that the difference
between these two classes of inhibitors in our experiments are due to histone hyperacetylation,
the results suggest that hydroxamic acids and benzamides have different modes of action and that
only hydroxamic acids may influence STAT5-mediated transcription.
HDACs are called co-repressors since they remove acetyl groups from histones, thereby
making the chromatin more condensed and less accessible to transcription. Consequently, HDAC
inhibition is expected to increase transcription (reviewed in Berger 2007). Yet, more recent
studies demonstrate that HDACs can also be found in active genes and may promote
transcription elongation (Z. Wang et al. 2009; Greer et al. 2015a). In our study, the upregulation
of Socs3 by HDAC inhibition is consistent with the concept that chromatin is more accessible to
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transcription. However, the downregulation of Cish expression by HDAC inhibition is more
perplexing. Since the HDAC inhibitors TSA and NaBu were previously reported to affect mRNA
stability (Krishnan et al. 2010), we also investigated this possibility using the HDAC5 inhibitor
in the presence of actinomycin D. Our results demonstrated that LMK-235 had no effect on the
mRNA stability of either Cish or Socs3 (Fig. 4.14).
In our study, the observed effects of HDAC inhibitors on gene expression are more likely
due to interference with other protein function than to inhibition of HDAC enzymatic activity.
Bromodomain and extra-terminal (BET) proteins bind to acetylated histones, recruit transcription
factors, and promote chromatin remodeling and transcription elongation (reviewed in Taniguchi
2016). Given the possible role of histone acetylation on STAT5-mediated transcription and the
fact that HDAC inhibitors have been reported to block mRNA elongation, (Greer et al. 2015a),
we hypothesized that these BET proteins could be mediating the effects of HDAC inhibitors in
our experiments. In order to investigate the involvement of BET proteins in STAT5-mediated
transcription, mature adipocytes were treated with the BET inhibitor JQ1, and Cish and Socs3
gene expression was analyzed (Fig. 4.15). The effects of JQ1 on Cish expression were strikingly
similar to those we had observed with LMK-235, suggesting that LMK-235 may indirectly
modulate BET protein function and, consequently, Cish expression. Surprisingly, JQ1 also
affected Socs3 expression in a manner similar to LMK-235; that is, JQ1 further enhanced GHinduced Socs3 expression. This was unexpected, since BET proteins are positively associated
with gene transcription, and BET inhibition would be expected to repress transcription. In
addition to the same pattern of induction and repression, the combination treatment with LMK235 and JQ1 had additive effects (Fig. 4.16). These results are consistent with previous reports
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that HDAC and BET inhibitors induce and repress similar genes and produce similar biological
effects (Bhadury et al. 2014).
Chromatin immunopreciptation (ChIP) was used to investigate the involvement of BET
proteins as well as STAT5 and RNA polymerase recruitment to Socs3 and Cish promoters.
Although HDAC and BET inhibition had divergent effects on the expression of Cish versus
Socs3, STAT5 binding patterns were similar for both genes, indicating that differences in STAT5
binding were not driving the changes in gene expression (Fig. 4.17C). Because Socs3 has been
reported to be a STAT3 target gene in the interleukin-6 (IL-6) signal transduction pathway (L.
Zhang et al. 2006), we investigated whether the binding of STAT3 to Socs3 and Cish promoters
correlated with the changes in gene expression. However, binding of STAT3 to the Cish
promoter was low, and no significant changes with inhibitors were detected (Fig. 4.17E). In the
Socs3 promoter, GH treatment decreased STAT3 binding (Fig. 4.17F). These results suggest that
Socs3 is not a STAT3 target gene in the GH signaling pathway in adipocytes.
In addition to the binding of STATs, we also examined the role and binding of BET
proteins. BRD4 binding levels to Socs3 and Cish promoters were comparable to IgG negative
(Fig. 4.23) control and generally unaffected by treatments (Figs. 4.18A-D). BRD2, however,
showed higher levels of binding than BDR4 and was recruited to the Cish promoter by GH. This
binding was inhibited by either LMK-235 or JQ1, suggesting that GH-induction of Cish is
dependent on BRD2 and that inhibitors displace BRD2 from the Cish TSS (Fig. 4.18E).
Consistent with this observation, the involvement of BRD2 in STAT5-mediated transcription has
been previously reported in human leukemia cells and Ba/F3 B cell line (Liu et al. 2014; Pinz et
al. 2015). BRD2 was not further recruited to the Socs3 promoter by GH, providing a possible
explanation for the divergent effects of HDAC and BET inhibition on Cish versus Socs3 gene
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expression (Fig. 4.18F). In addition, acetylation levels at Cish TSS (Figs. 4.20C and 4.21C) were
about two-fold higher than Socs3 TSS (Figs. 4.20D and 4.21D), and concomitant with decreased
BRD2 binding to Cish TSS by LMK-235, histone acetylation levels were unexpectedly reduced
in the same region and increased at the coding region (Figs. 4.20E and 4.21E). Although we
could not detect increased BRD2 binding to the coding regions (data not shown), these
observations further support the hypothesis that BRD2, which is required for the GH induction of
Cish, is being displaced from the TSS by LMK-235, thus affecting GH-induced gene expression.
In agreement with this hypothesis, a genome-wide approach demonstrated that HDAC inhibitors
shifted BRD4 binding from acetylated promoters and enhancers to newly acetylated sites in gene
bodies and intergenic regions (Greer et al. 2015). In addition, we also found that the HDAC
inhibitor LMK-235 substantially decreased BRD2 protein levels (Fig. 4.25). Therefore, not only
is BRD2 being displaced from the Cish promoter, but its availability in the cell is also lower.
This is a novel observation. In fact, a study performed in HeLa cells showed that HDAC
inhibitors caused selective depletion of bromodomain containing proteins, with the exception of
BET proteins that were upregulated (Mackmull et al. 2015).
BRD2 has been reported to interact with components of the transcriptional machinery,
including RNA Polymerase II, serving as a scaffold protein (Peng et al. 2007; LeRoy, Rickards,
and Flint 2008). When RNA polymerase binding was analyzed, GH-mediated recruitment of Pol
II to the Cish promoter was decreased by LMK-235 or JQ1 (Fig. 4.19A). Whether the reduced
levels of activated Pol II binding to the coding region of Cish (Fig. 4.19C) are completely
explained by decreased Pol II recruitment or further effects on mRNA elongation, needs further
investigation. LMK-235 increased Pol II recruitment to the Socs3 promoter in either V or GH
conditions, JQ1 had no effects on GH recruitment of Pol II to Socs3 TSS compared to DMSO
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control (Fig. 4.19B). Therefore, the upregulation of Socs3 by JQ1 was not explained by increased
Pol II recruitment. However, the binding of Pol II phosphorylated at Ser2 to the coding region of
Socs3 was highly increased by JQ1 (Fig. 4.19D). Since this is a well-known marker of elongation
(reviewed in Bowman and Kelly 2014), these data suggest that JQ1 is positively impacting Socs3
mRNA elongation.
The upregulation of Socs3 by JQ1 was initially challenging to explain. However,
extensive research performed in the HIV field has shed light on how the inhibition of proteins
that promote transcription elongation could upregulate some genes. In fact, the phenomenon does
not necessarily involve BET proteins but an off target effect of JQ1 (Bartholomeeusen et al.
2012b) and other BET inhibitors (Lu et al. 2016) that results in the release of elongation factor PTEFb from its inhibitory complex. HEXIM1 acts to inhibit P-TEFb when they are both
associated with 7SK snRNA (Michels et al. 2004). In our experiments, the decreased association
between Cyclin T1 (the regulatory subunit of P-TEFb) and HEXIM1 following JQ1 exposure,
coupled with the increased association between BRD2 and Cyclin T1 (Fig. 4.23), as well as the
upregulation of HEXIM1 (Figs. 4.24 and 4.25) support the hypothesis that JQ1 interferes with
the binding of P-TEFb to its inhibitory complex. Disruption of the P-TEFb inhibitory complex
shifts the equilibrium to free P-TEFb form and causes the cell to recognize that HEXIM1 levels
are insufficient. Activation of cellular feedback mechanisms upregulate HEXIM1 expression to
reassemble the 7SK snRNA inhibitory complex. Most studies have focused on BRD4
interactions with the P-TEFb complex via its Cyclin T1 subunit. Moreover, only BRD4
possesses a C-terminal segment called P-TEFb interacting domain (PID) that can actively
dissociate P-TEFb from HEXIM1. However, depletion of that domain does not completely
eliminate the association between BRD4 and CyclinT1 (Schröder et al. 2012; Taniguchi 2016),
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indicating that another region of BET proteins may facilitate this interaction. Our study confirms
that BRD2 can also be present in a protein complex with Cyclin T1 (Fig. 4.23). Whether this is a
direct interaction or mediated by other proteins will require further investigation.
While more studies will be necessary to better explain the divergent transcriptional
regulation of Socs3 and Cish, we have created a hypothetical model (Fig. 5.1), showing that GH
upregulation of Cish is dependent on BRD2 recruitment to the promoter, which leads to
recruitment of RNA polymerase II and P-TEFb for transcription elongation. When JQ1 is
present, it displaces BRD2 from the Cish promoter, thus decreasing its gene expression. GH
upregulation of Socs3, however, is likely dependent on other factors. Since P-TEFb when not
bound to its inhibitory complex, is reported to associate with either BRD4 or the super
elongation complex (SEC) (Smith, Lin, and Shilatifard 2011; reviewed in Q. Zhou, Li, and Price
2012), we hypothesize that SEC is responsible for recruiting P-TEFb to the Socs3 promoter.
When JQ1 is present, it disrupts the interaction between P-TEFb and HEXIM1, allowing more PTEFb to be available for recruitment by SEC, which could further increase GH-induced Socs3
expression (Fig. 5.1).
To confirm the model proposed, genome-wide approaches could be used to investigate
how BRD2 distribution in the chromatin is affected by HDAC and BET inhibitors. In addition, to
gain a more complete picture of proteins involved in the GH-induced transcription regulation of
Socs3 and Cish, methods targeting chromatin in a site-specific manner would be ideal. Several
techniques have been described in which a specific part of the genome is isolated and associated
proteins are analyzed. Reverse ChIP analysis, for example, is one such method. In another
method performed in Saccharomyces cerevisiae, a specific area of the chromosome is targeted
via site-specific recombination in tandem with affinity purification (Hamperl et al. 2014).
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Moreover, methods performed with CRISPR technology use the CRISPR associated protein 9
(Cas9) and guide RNA (gRNA) to directly purify a discrete section of the chromatin, and then
the associated proteins are identified by mass spectrometry (Waldrip et al. 2014; Tsui et al.
2018). This type of technique could confirm if any components of the SEC protein complex are
present at the Socs3 promoter, and could identify differentially recruited transcription factors,
chromatin remodeling factors and histone markers.
SOCS3 and CISH are members of the family of suppressors of cytokine signaling. All
members of this family possess a conserved Src homology 2 (SH2) domain and a C-terminal
SOCS box. The SH2 domain inhibits the signaling pathway via direct or competitive binding
inhibition to phosphorylated intermediates while the SOCS box is associated with ubiquitination
machinery targeting proteins to the proteasome for degradation (Babon et al. 2009). Studies
comparing SOCS proteins have revealed different mechanisms of inhibition among the family
members. SOCS3 and SOCS1 possess a kinase inhibitory region (Sasaki et al. 1999) that is
responsible for Janus tyrosine kinase (JAK) inhibition. In addition, SOCS3 can bind
simultaneously to JAK and cytokine receptors revealing higher levels of specificity (Babon et al.
2012; Kershaw et al. 2013). On the other hand, CISH does not interact with JAKs. The binding
of CISH to more distal tyrosine residues of GHR leads to direct competition with STAT5
binding sites. Alternatively, CISH is involved in a proteasome-dependent mechanism that may
induce GHR internalization and destruction of GHR-JAK2-CISH complexes (Ram and Waxman
1999; Landsman and Waxman 2005). Differences in the activation patterns of Socs3 and Cish
have been described (Adams et al. 1998; Tollet-Egnell et al. 1999) and we have confirmed these
differences in our studies.
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The fast and acute upregulation of Socs3 represents a classical feed-back loop. Cish,
however, is upregulated later and its expression level remains highly elevated even after 48 hours
of GH stimulation. The roles of SOCS3 and CISH as suppressors of JAK-STAT signaling in
adipocytes could be further investigated by introducing mutations at residues important for the
interactions between SOCS proteins and GH receptor or JAKs. Alternatively, siRNA-mediated
knockdowns of SOCS3 or CISH could be used to examine STAT5 phosphorylation and direct
effects of this signaling pathway.
Thus, despite similar protein structures and roles in inhibiting cytokine signaling
pathways, differences in gene activation patterns and divergent responses to HDAC and BET
inhibition demonstrate that these very closely related proteins might have different functions, at
least in the context of cultured murine adipocytes. This project underscores the complexity of
epigenetic modulation, as the same inhibitors have such profound and opposite effects on these
very closely related proteins. Since several HDAC and BET inhibitors are currently in clinical
trials and some of their effects described here are not due to direct enzymatic inhibition of their
protein targets. Our research highlights the implications of possible off-target effects of these
pharmacological inhibitors and the importance of thoroughly investigating their full effects.
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Figure 5.1. Model for potential differences between Socs3 and Cish gene expression. Under normal conditions, when 3T3-L1
adipocytes are stimulated with GH, the JAK-STAT signaling pathway is activated. STAT5 dimerizes and binds to STAT binding sites
within the Cish and Socs3 promoters. For the Cish promoter, BRD2 is recruited by GH treatment. Then, BRD2 binds acetylated
(figure caption cont’d.)
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histones and recruits RNA polymerase II and the positive elongation factor (P-TEFb). P-TEFb
phosphorylates Ser2 on the RNA pol II CTD to promote elongation. When the cells are pretreated with JQ1 before GH stimulation, BRD2 is displaced from chromatin. Therefore, RNA
polymerase and P-TEFb recruitment to Cish promoter is decreased. At the Socs3 promoter, GH
treatment stimulates the recruitment of P-TEFb by the super elongation complex (SEC). P-TEFb
then phosphorylates RNA Pol II and productive elongation occurs. When the cells are pre-treated
with JQ1, P-TEFb is released from its inhibitory complex and then becomes more available to
further promote Socs3 elongation in the presence of GH.

81

Bibliography
Adams, T E, J A Hansen, R Starr, N A Nicola, D J Hilton, and N Billestrup. 1998. “Growth
Hormone Preferentially Induces the Rapid, Transient Expression of SOCS-3, a Novel
Inhibitor of Cytokine Receptor Signaling.” The Journal of Biological Chemistry 273 (3):
1285–87. https://doi.org/10.1074/JBC.273.3.1285.
Adelman, Karen, and John T Lis. 2012. “Promoter-Proximal Pausing of RNA Polymerase II:
Emerging Roles in Metazoans.” Nature Reviews. Genetics 13 (10): 720–31.
https://doi.org/10.1038/nrg3293.
Aravind, L., Vivek Anantharaman, Santhanam Balaji, M. Mohan Babu, and Lakshminarayan M.
Iyer. 2005. “The Many Faces of the Helix-Turn-Helix Domain: Transcription Regulation
and Beyond.” FEMS Microbiology Reviews 29 (2): 231–62.
https://doi.org/10.1016/j.fmrre.2004.12.008.
Arita, Yukio, Shinji Kihara, Noriyuki Ouchi, Masahiko Takahashi, Kazuhisa Maeda, Jun-Ichiro
Miyagawa, Kikuko Hotta, et al. 1999. “Paradoxical Decrease of an Adipose-Specific
Protein, Adiponectin, in Obesity.” http://www.idealibrary.com.
Aronne, Louis J. 2002. “Classification of Obesity and Assessment of Obesity-Related Health
Risks.” Obesity Research 10 (S12): 105S–115S. https://doi.org/10.1038/oby.2002.203.
Babon, Jeffrey J., Nadia J. Kershaw, James M. Murphy, Leila N. Varghese, Artem Laktyushin,
Samuel N. Young, Isabelle S. Lucet, Raymond S. Norton, and Nicos A. Nicola. 2012.
“Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition
and the Basis of Its Specificity.” Immunity 36 (2): 239–50.
https://doi.org/10.1016/J.IMMUNI.2011.12.015.
Babon, Jeffrey J, Jennifer K Sabo, Jian-Guo Zhang, Nicos A Nicola, and Raymond S Norton.
2009. “The SOCS Box Encodes a Hierarchy of Affinities for Cullin5: Implications for
Ubiquitin Ligase Formation and Cytokine Signalling Suppression.” Journal of Molecular
Biology 387 (1): 162–74. https://doi.org/10.1016/J.JMB.2009.01.024.
Bartholomeeusen, Koen, Koh Fujinaga, Yanhui Xiang, and B Matija Peterlin. 2013. “Histone
Deacetylase Inhibitors (HDACis) That Release the Positive Transcription Elongation Factor
b (P-TEFb) from Its Inhibitory Complex Also Activate HIV Transcription*.”
https://doi.org/10.1074/jbc.M113.464834.
Bartholomeeusen, Koen, Yanhui Xiang, Koh Fujinaga, and B. Matija Peterlin. 2012a.
“Bromodomain and Extra-Terminal (BET) Bromodomain Inhibition Activate Transcription
via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK
Small Nuclear Ribonucleoprotein.” Journal of Biological Chemistry 287 (43): 36609–16.
https://doi.org/10.1074/jbc.M112.410746.
82

Bartholomeeusen, Koen, Yanhui Xiang, Koh Fujinaga, and B Matija Peterlin. 2012b.
“Bromodomain and Extra-Terminal (BET) Bromodomain Inhibition Activate Transcription
via Transient Release of Positive Transcription Elongation Factor b (P-TEFb) from 7SK
Small Nuclear Ribonucleoprotein *.” https://doi.org/10.1074/jbc.M112.410746.
Bastard, Jean-Philippe, Mustapha Maachi, Jeanne Tran van Nhieu, Claude Jardel, Eric Bruckert,
André Grimaldi, Jean-Jacques Robert, Jacqueline Capeau, and Bernard Hainque. 2002.
“Adipose Tissue IL-6 Content Correlates with Resistance to Insulin Activation of Glucose
Uptake Both in Vivo and in Vitro.” The Journal of Clinical Endocrinology & Metabolism 87
(5): 2084–89. https://doi.org/10.1210/jcem.87.5.8450.
Berger, Shelley L. 2007. “The Complex Language of Chromatin Regulation during
Transcription.” Nature 447 (7143): 407–12. https://doi.org/10.1038/nature05915.
Bhadury, Joydeep, Lisa M Nilsson, Somsundar Veppil Muralidharan, Lydia C Green, Zhoulei Li,
Emily M Gesner, Henrik C Hansen, Ulrich B Keller, Kevin G McLure, and Jonas A
Nilsson. 2014. “BET and HDAC Inhibitors Induce Similar Genes and Biological Effects
and Synergize to Kill in Myc-Induced Murine Lymphoma.” Proceedings of the National
Academy of Sciences of the United States of America 111 (26): E2721-30.
https://doi.org/10.1073/pnas.1406722111.
Bowman, Elizabeth A, and William G Kelly. 2014. “RNA Polymerase II Transcription
Elongation and Pol II CTD Ser2 Phosphorylation: A Tail of Two Kinases.” Nucleus 5 (3):
224. https://doi.org/10.4161/NUCL.29347.
Busch, Steven J., and Paolo Sassone-Corsi. 1990. “Dimers, Leucine Zippers and DNA-Binding
Domains.” Trends in Genetics 6 (C): 36–40. https://doi.org/10.1016/0168-9525(90)90071D.
Caroli, Annalisa, Maria Teresa Cardillo, Roberto Galea, and Luigi M. Biasucci. 2013. “Potential
Therapeutic Role of MicroRNAs in Ischemic Heart Disease.” Journal of Cardiology 61 (5):
315–20. https://doi.org/10.1016/J.JJCC.2013.01.012.
Cassandri, Matteo, Artem Smirnov, Flavia Novelli, Consuelo Pitolli, Massimiliano Agostini,
Michal Malewicz, Gerry Melino, and Giuseppe Raschellà. 2017. “Zinc-Finger Proteins in
Health and Disease.” Cell Death Discovery 3 (November): 17071.
https://doi.org/10.1038/cddiscovery.2017.71.
Catania, Annunziata, Carlo Iavarone, Stella M. Carlomagno, and Mario Chiariello. 2006.
“Selective Transcription and Cellular Proliferation Induced by PDGF Require Histone
Deacetylase Activity.” Biochemical and Biophysical Research Communications 343 (2):
544–54. https://doi.org/10.1016/J.BBRC.2006.03.013.
Chatterjee, Tapan K, Joshua E Basford, Ellen Knoll, Wilson S Tong, Victor Blanco, Andra L
Blomkalns, Steven Rudich, Alex B Lentsch, David Y Hui, and Neal L Weintraub. 2014.
83

“HDAC9 Knockout Mice Are Protected from Adipose Tissue Dysfunction and Systemic
Metabolic Disease during High-Fat Feeding.” Diabetes 63 (1): 176–87.
https://doi.org/10.2337/db13-1148.
Chatterjee, Tapan K, Gila Idelman, Victor Blanco, Andra L Blomkalns, Mark G Piegore, Daniel
S Weintraub, Santosh Kumar, et al. 2011. “Histone Deacetylase 9 Is a Negative Regulator
of Adipogenic Differentiation.” The Journal of Biological Chemistry 286 (31): 27836–47.
https://doi.org/10.1074/jbc.M111.262964.
Chen, Jingjing, Ilaria Guccini, Diletta Di Mitri, Daniela Brina, Ajinkya Revandkar, Manuela
Sarti, Emiliano Pasquini, et al. 2018. “Compartmentalized Activities of the Pyruvate
Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.” Nature Genetics 50 (2):
219–28. https://doi.org/10.1038/s41588-017-0026-3.
Chia, Dennis J. 2014. “Minireview: Mechanisms of Growth Hormone-Mediated Gene
Regulation.” Molecular Endocrinology (Baltimore, Md.) 28 (7): 1012–25.
https://doi.org/10.1210/me.2014-1099.
Chikuma, Shunsuke, Mitsuhiro Kanamori, Setsuko Mise-Omata, and Akihiko Yoshimura. 2017.
“Suppressors of Cytokine Signaling: Potential Immune Checkpoint Molecules for Cancer
Immunotherapy.” Cancer Science 108 (4): 574–80. https://doi.org/10.1111/cas.13194.
Chusyd, Daniella E, Donghai Wang, Derek M Huffman, and Tim R Nagy. 2016. “Relationships
between Rodent White Adipose Fat Pads and Human White Adipose Fat Depots.” Frontiers
in Nutrition 3: 10. https://doi.org/10.3389/fnut.2016.00010.
Cinti, Saverio. 2012. “The Adipose Organ at a Glance.” Disease Models & Mechanisms 5 (5):
588–94. https://doi.org/10.1242/dmm.009662.
De, W, B Bréant, P Czernichow, and M Asfari. 1995. “Growth Hormone (GH) and Prolactin
(PRL) Regulate IGFBP-3 Gene Expression in Rat Beta-Cells.” Molecular and Cellular
Endocrinology 114 (1–2): 43–50. http://www.ncbi.nlm.nih.gov/pubmed/8674850.
Decker, T, and P Kovarik. 1999. “Transcription Factor Activity of STAT Proteins: Structural
Requirements and Regulation by Phosphorylation and Interacting Proteins.” CMLS, Cell.
Mol. Life Sci. Vol. 55. https://link.springer.com/content/pdf/10.1007/s000180050393.pdf.
Dejligbjerg, Marielle, Morten Grauslund, Thomas Litman, Laura Collins, Xiaozhong Qian,
Michael Jeffers, Henri Lichenstein, Peter Jensen, and Maxwell Sehested. 2008.
“Differential Effects of Class I Isoform Histone Deacetylase Depletion and Enzymatic
Inhibition by Belinostat or Valproic Acid in HeLa Cells.” Molecular Cancer 7 (1): 70.
https://doi.org/10.1186/1476-4598-7-70.
Dumortier, Olivier, Charlotte Hinault, and Emmanuel Van Obberghen. 2013. “Cell Metabolism
Review MicroRNAs and Metabolism Crosstalk in Energy Homeostasis.” Cell Metabolism
18: 312–24. https://doi.org/10.1016/j.cmet.2013.06.004.
84

Duvic, M., R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J. H. Chiao, et al. 2007. “Phase 2
Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory
Cutaneous T-Cell Lymphoma (CTCL).” Blood 109 (1): 31–39.
https://doi.org/10.1182/blood-2006-06-025999.
Eckschlager, Tomas, Johana Plch, Marie Stiborova, and Jan Hrabeta. 2017. “Histone
Deacetylase Inhibitors as Anticancer Drugs.” International Journal of Molecular Sciences
18 (7). https://doi.org/10.3390/ijms18071414.
Endo, Takaho A., Masaaki Masuhara, Masahiro Yokouchi, Ritsu Suzuki, Hiroshi Sakamoto,
Kaoru Mitsui, Akira Matsumoto, et al. 1997. “A New Protein Containing an SH2 Domain
That Inhibits JAK Kinases.” Nature 387 (6636): 921–24. https://doi.org/10.1038/43213.
Filippakopoulos, Panagis, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov,
Elizabeth M Morse, et al. 2010. “Selective Inhibition of BET Bromodomains.” Nature 468
(7327): 1067–73. https://doi.org/10.1038/nature09504.
Fischle, Wolfgang, Franck Dequiedt, Michael J Hendzel, Matthew G Guenther, Mitchell A
Lazar, Wolfgang Voelter, and Eric Verdin. 2002a. “Enzymatic Activity Associated with
Class II HDACs Is Dependent on a Multiprotein Complex Containing HDAC3 and
SMRT/N-CoR.” Molecular Cell 9 (1): 45–57. https://doi.org/10.1016/S10972765(01)00429-4.
———. 2002b. “Enzymatic Activity Associated with Class II HDACs Is Dependent on a
Multiprotein Complex Containing HDAC3 and SMRT/N-CoR.” Molecular Cell 9 (1): 45–
57. https://doi.org/10.1016/S1097-2765(01)00429-4.
Fleenor, Don, Ramamani Arumugam, and Michael Freemark. 2006. “Growth Hormone and
Prolactin Receptors in Adipogenesis: STAT-5 Activation, Suppressors of Cytokine
Signaling, and Regulation of Insulin-like Growth Factor I.” Hormone Research 66 (3): 101–
10. https://doi.org/10.1159/000093667.
Florence, Brian, and Douglas V Faller. 2001. “YOU BET-CHA: A NOVEL FAMILY OF
TRANSCRIPTIONAL REGULATORS.” Frontiers in Bioscience. Vol. 6.
https://pdfs.semanticscholar.org/221d/f87ba0956a63e3751ca0d4e1b6d77f7fed8b.pdf.
Floyd, Z Elizabeth, and Jacqueline M Stephens. 2003. “STAT5A Promotes Adipogenesis in
Nonprecursor Cells and Associates with the Glucocorticoid Receptor during Adipocyte
Differentiation.” Diabetes 52 (2): 308–14. https://doi.org/10.2337/DIABETES.52.2.308.
for Disease Control, Centers. 2017. “National Diabetes Statistics Report, 2017 Estimates of
Diabetes and Its Burden in the United States Background.”
http://www.diabetes.org/assets/pdfs/basics/cdc-statistics-report-2017.pdf.
Fuller, Scott, Allison J. Richard, David M. Ribnicky, Robbie Beyl, Randall Mynatt, and
85

Jacqueline M. Stephens. 2014. “St. John’s Wort Has Metabolically Favorable Effects on
Adipocytes In Vivo.” Evidence-Based Complementary and Alternative Medicine 2014: 1–8.
https://doi.org/10.1155/2014/862575.
Gastaldelli, Amalia. 2011. “Role of Beta-Cell Dysfunction, Ectopic Fat Accumulation and
Insulin Resistance in the Pathogenesis of Type 2 Diabetes Mellitus.” Diabetes Research and
Clinical Practice 93 (August): S60–65. https://doi.org/10.1016/S0168-8227(11)70015-8.
Gastaldelli, Amalia, Yoshinori Miyazaki, Maura Pettiti, Masafumi Matsuda, Srihanth Mahankali,
Eleonora Santini, Ralph A. DeFronzo, and Ele Ferrannini. 2002. “Metabolic Effects of
Visceral Fat Accumulation in Type 2 Diabetes.” The Journal of Clinical Endocrinology &
Metabolism 87 (11): 5098–5103. https://doi.org/10.1210/jc.2002-020696.
Glauben, Rainer, and Britta Siegmund. 2011. “Inhibition of Histone Deacetylases in
Inflammatory Bowel Diseases.” Molecular Medicine 17 (5–6): 426–33.
https://doi.org/10.2119/molmed.2011.00069.
Gottschling, D E, O M Aparicio, B L Billington, and V A Zakian. 1990. “Position Effect at S.
Cerevisiae Telomeres: Reversible Repression of Pol II Transcription.” Cell 63 (4): 751–62.
http://www.ncbi.nlm.nih.gov/pubmed/2225075.
Goupille, Olivier, Tipparat Penglong, Zahra Kadri, Marine Granger-Locatelli, Suthat Fucharoen,
Leila Maouche-Chrétien, Stéphane Prost, Philippe Leboulch, and Stany Chrétien. 2016.
“Inhibition of the Acetyl Lysine-Binding Pocket of Bromodomain and Extraterminal
Domain Proteins Interferes with Adipogenesis.” Biochemical and Biophysical Research
Communications 472 (4): 624–30. https://doi.org/10.1016/j.bbrc.2016.03.013.
Gräff, Johannes, Damien Rei, Ji-Song Guan, Wen-Yuan Wang, Jinsoo Seo, Krista M. Hennig,
Thomas J. F. Nieland, et al. 2012. “An Epigenetic Blockade of Cognitive Functions in the
Neurodegenerating Brain.” Nature 483 (7388): 222–26.
https://doi.org/10.1038/nature10849.
Green, Howard, and Olanlyl Kehinde. 1976. “Spontaneous Heritable Changes Leading to
Increased Adipose Conversion in 3T3 Cells.” Cell 7 (1): 105–13.
https://doi.org/10.1016/0092-8674(76)90260-9.
Greer, Celeste B., Yoshiaki Tanaka, Yoon Jung Kim, Peng Xie, Michael Q. Zhang, In-Hyun
Park, and Tae Hoon Kim. 2015a. “Histone Deacetylases Positively Regulate Transcription
through the Elongation Machinery.” Cell Reports 13 (7): 1444–55.
https://doi.org/10.1016/J.CELREP.2015.10.013.
———. 2015b. “Histone Deacetylases Positively Regulate Transcription through the Elongation
Machinery.” Cell Reports 13 (7): 1444–55. https://doi.org/10.1016/j.celrep.2015.10.013.
Grenn, Howard, and Mark Meuth. 1974. “An Established Pre-Adipose Cell Line and Its
Differentiation in Culture.” Cell 3 (2): 127–33. https://doi.org/10.1016/00928674(74)90116-0.
86

Gu, Wei, and Robert G Roeder. 1997. “Activation of P53 Sequence-Specific DNA Binding by
Acetylation of the P53 C-Terminal Domain.” Cell 90 (4): 595–606.
https://doi.org/10.1016/S0092-8674(00)80521-8.
Guan, Ji-Song, Stephen J. Haggarty, Emanuela Giacometti, Jan-Hermen Dannenberg, Nadine
Joseph, Jun Gao, Thomas J. F. Nieland, et al. 2009. “HDAC2 Negatively Regulates
Memory Formation and Synaptic Plasticity.” Nature 459 (7243): 55–60.
https://doi.org/10.1038/nature07925.
Gyuris, Aron, Diana J Donovan, Kimberly A Seymour, Lindsay A Lovasco, Nathaniel R
Smilowitz, Anthony L P Halperin, Jan E Klysik, and Richard N Freiman. 2009. “The
Chromatin-Targeting Protein Brd2 Is Required for Neural Tube Closure and
Embryogenesis.” Biochimica et Biophysica Acta 1789 (5): 413–21.
https://doi.org/10.1016/j.bbagrm.2009.03.005.
Ha, Chang Hoon, Ji Young Kim, Jinjing Zhao, Weiye Wang, Bong Sook Jhun, Chelsea Wong,
and Zheng Gen Jin. 2010. “PKA Phosphorylates Histone Deacetylase 5 and Prevents Its
Nuclear Export, Leading to the Inhibition of Gene Transcription and Cardiomyocyte
Hypertrophy.” Proceedings of the National Academy of Sciences of the United States of
America 107 (35): 15467–72. https://doi.org/10.1073/pnas.1000462107.
Haberland, Michael, Rusty L Montgomery, and Eric N Olson. 2009. “The Many Roles of
Histone Deacetylases in Development and Physiology: Implications for Disease and
Therapy.” Nature Reviews. Genetics 10 (1): 32–42. https://doi.org/10.1038/nrg2485.
Haigis, Marcia C, and David A Sinclair. 2010. “Mammalian Sirtuins: Biological Insights and
Disease Relevance.” Annual Review of Pathology 5: 253–95.
https://doi.org/10.1146/annurev.pathol.4.110807.092250.
Hamperl, Stephan, Christopher R. Brown, Jorge Perez-Fernandez, Katharina Huber, Manuel
Wittner, Virginia Babl, Ulrike Stöckl, et al. 2014. “Purification of Specific Chromatin
Domains from Single-Copy Gene Loci in Saccharomyces Cerevisiae.” In , 329–41. Humana
Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-706-8_26.
Hata, Akiko, and Judy Lieberman. 2015. “Dysregulation of MicroRNA Biogenesis and Gene
Silencing in Cancer.” Science Signaling 8 (368): re3.
https://doi.org/10.1126/scisignal.2005825.
He, Nanhai, Andrea C Pezda, and Qiang Zhou. 2006. “Modulation of a P-TEFb Functional
Equilibrium for the Global Control of Cell Growth and Differentiation.” Molecular and
Cellular Biology 26 (19): 7068–76. https://doi.org/10.1128/MCB.00778-06.
Hilton, D. J., R. T. Richardson, W. S. Alexander, E. M. Viney, T. A. Willson, N. S. Sprigg, R.
Starr, S. E. Nicholson, D. Metcalf, and N. A. Nicola. 1998. “Twenty Proteins Containing a
C-Terminal SOCS Box Form Five Structural Classes.” Proceedings of the National
87

Academy of Sciences 95 (1): 114–19. https://doi.org/10.1073/pnas.95.1.114.
Hochberg, Irit, Quynh T. Tran, Ariel L. Barkan, Alan R. Saltiel, William F. Chandler, and Dave
Bridges. 2015. “Gene Expression Signature in Adipose Tissue of Acromegaly Patients.”
Edited by Martin Young. PLOS ONE 10 (6): e0129359.
https://doi.org/10.1371/journal.pone.0129359.
Holmlund, T, M J Lindberg, D Grander, and A E Wallberg. 2013. “GCN5 Acetylates and
Regulates the Stability of the Oncoprotein E2A-PBX1 in Acute Lymphoblastic Leukemia.”
Leukemia 27 (3): 578–85. https://doi.org/10.1038/leu.2012.265.
Hotamisligil, G S, N S Shargill, and B M Spiegelman. 1993. “Adipose Expression of Tumor
Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance.” Science (New
York, N.Y.) 259 (5091): 87–91. http://www.ncbi.nlm.nih.gov/pubmed/7678183.
Houzelstein, Denis, Simon L Bullock, Denise E Lynch, Elena F Grigorieva, Valerie A Wilson,
and Rosa S P Beddington. 2002. “Growth and Early Postimplantation Defects in Mice
Deficient for the Bromodomain-Containing Protein Brd4.” Molecular and Cellular Biology
22 (11): 3794–3802. https://doi.org/10.1128/MCB.22.11.3794-3802.2002.
Inoue, A, and D Fujimoto. 1969. “Enzymatic Deacetylation of Histone.” Biochemical and
Biophysical Research Communications 36 (1): 146–50.
http://www.ncbi.nlm.nih.gov/pubmed/5796748.
Jang, Moon Kyoo, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N. Brady, and
Keiko Ozato. 2005. “The Bromodomain Protein Brd4 Is a Positive Regulatory Component
of P-TEFb and Stimulates RNA Polymerase II-Dependent Transcription.” Molecular Cell
19 (4): 523–34. https://doi.org/10.1016/J.MOLCEL.2005.06.027.
Jia-YiWei, Qiu-NanLu, Wan-MingLi, and Wei He. 2015. “Intracellular Translocation of Histone
Deacetylase 5 Regulates Neuronal Cell Apoptosis.” Brain Research 1604 (April): 15–24.
https://doi.org/10.1016/J.BRAINRES.2015.01.043.
Jiang, Xiaoting, Xin Ye, Wei Guo, Hongyun Lu, and Zhanguo Gao. 2014. “Inhibition of HDAC3
Promotes Ligand-Independent PPARγ Activation by Protein Acetylation.” Journal of
Molecular Endocrinology 53 (2): 191–200. https://doi.org/10.1530/JME-14-0066.
Jones, Philip, Sergio Altamura, Raffaele De Francesco, Paola Gallinari, Armin Lahm, Petra
Neddermann, Michael Rowley, Sergio Serafini, and Christian Steinkühler. 2008. “Probing
the Elusive Catalytic Activity of Vertebrate Class IIa Histone Deacetylases.” Bioorganic &
Medicinal Chemistry Letters 18 (6): 1814–19. https://doi.org/10.1016/j.bmcl.2008.02.025.
Kaltenecker, Doris, Kristina M. Mueller, Pia Benedikt, Ursula Feiler, Madeleine Themanns,
Michaela Schlederer, Lukas Kenner, Martina Schweiger, Guenter Haemmerle, and Richard
Moriggl. 2017. “Adipocyte STAT5 Deficiency Promotes Adiposity and Impairs Lipid
Mobilisation in Mice.” Diabetologia 60 (2): 296–305. https://doi.org/10.1007/s00125-01688

4152-8.
Kanda, Hajime, Sanshiro Tateya, Yoshikazu Tamori, Ko Kotani, Ken-ichi Hiasa, Riko Kitazawa,
Sohei Kitazawa, et al. 2006. “MCP-1 Contributes to Macrophage Infiltration into Adipose
Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity.” The Journal of Clinical
Investigation 116 (6): 1494–1505. https://doi.org/10.1172/JCI26498.
Kao, Hung-Ying, André Verdel, Chih-Cheng Tsai, Cynthia Simon, Henry Juguilon, and Saadi
Khochbin. 2001. “Mechanism for Nucleocytoplasmic Shuttling of Histone Deacetylase 7*.”
https://doi.org/10.1074/jbc.M107631200.
Kelesidis, Theodore, Iosif Kelesidis, Sharon Chou, and Christos S Mantzoros. 2010. “Narrative
Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications.”
Annals of Internal Medicine 152 (2): 93–100. https://doi.org/10.7326/0003-4819-152-2201001190-00008.
Kershaw, Nadia J, James M Murphy, Nicholas P D Liau, Leila N Varghese, Artem Laktyushin,
Eden L Whitlock, Isabelle S Lucet, Nicos A Nicola, and Jeffrey J Babon. 2013. “SOCS3
Binds Specific Receptor-JAK Complexes to Control Cytokine Signaling by Direct Kinase
Inhibition.” Nature Structural & Molecular Biology 20 (4): 469–76.
https://doi.org/10.1038/nsmb.2519.
Kim, Hyun-Jung, and Suk-Chul Bae. 2011. “Histone Deacetylase Inhibitors: Molecular
Mechanisms of Action and Clinical Trials as Anti-Cancer Drugs.” American Journal of
Translational Research 3 (2): 166–79. http://www.ncbi.nlm.nih.gov/pubmed/21416059.
Kim, T K, and T Maniatis. 1996. “Regulation of Interferon-Gamma-Activated STAT1 by the
Ubiquitin-Proteasome Pathway.” Science (New York, N.Y.) 273 (5282): 1717–19.
http://www.ncbi.nlm.nih.gov/pubmed/8781235.
Kintscher, Ulrich, Martin Hartge, Katharina Hess, Anna Foryst-Ludwig, Markus Clemenz,
Martin Wabitsch, Pamela Fischer-Posovszky, et al. 2008. “T-Lymphocyte Infiltration in
Visceral Adipose Tissue.” Arteriosclerosis, Thrombosis, and Vascular Biology 28 (7):
1304–10. https://doi.org/10.1161/ATVBAHA.108.165100.
Klampfer, Lidija, Jie Huang, Laurie-Anne Swaby, and Leonard Augenlicht. n.d.
“REQUIREMENT OF HISTONE DEACETYLASE ACTIVITY FOR SIGNALING BY
STAT1 Running Title: HDAC and Signaling by IFNγ.” Accessed July 5, 2018.
http://www.jbc.org/.
Klöting, Nora, Mathias Fasshauer, Arne Dietrich, Peter Kovacs, Michael R. Schön, Matthias
Kern, Michael Stumvoll, and Matthias Blüher. 2010. “Insulin-Sensitive Obesity.” American
Journal of Physiology-Endocrinology and Metabolism 299 (3): E506–15.
https://doi.org/10.1152/ajpendo.00586.2009.
Krebs, Danielle L., and Douglas J. Hilton. 2001. “SOCS Proteins: Negative Regulators of
89

Cytokine Signaling.” Stem Cells 19 (5): 378–87. https://doi.org/10.1634/stemcells.19-5-378.
Krishnan, M, A B Singh, J J Smith, A Sharma, X Chen, S Eschrich, T J Yeatman, R D
Beauchamp, and P Dhawan. 2010. “HDAC Inhibitors Regulate Claudin-1 Expression in
Colon Cancer Cells through Modulation of MRNA Stability.” Oncogene 29 (2): 305–12.
https://doi.org/10.1038/onc.2009.324.
Kruglikov, Ilja L, and Philipp E Scherer. 2016. “Dermal Adipocytes: From Irrelevance to
Metabolic Targets?” Trends in Endocrinology and Metabolism: TEM 27 (1): 1–10.
https://doi.org/10.1016/j.tem.2015.11.002.
Landsman, Tanya, and David J Waxman. 2005. “Role of the Cytokine-Induced SH2 DomainContaining Protein CIS in Growth Hormone Receptor Internalization.” The Journal of
Biological Chemistry 280 (45): 37471–80. https://doi.org/10.1074/jbc.M504125200.
Lavu, Siva, Olivier Boss, Peter J. Elliott, and Philip D. Lambert. 2008. “Sirtuins — Novel
Therapeutic Targets to Treat Age-Associated Diseases.” Nature Reviews Drug Discovery 7
(10): 841–53. https://doi.org/10.1038/nrd2665.
Leder, Aya, and Philip Leder. 1975. “Butyric Acid, a Potent Inducer of Erythroid Differentiation
in Cultured Erythroleukemic Cells.” Cell 5 (3): 319–22. https://doi.org/10.1016/00928674(75)90107-5.
LeRoy, Gary, Brenden Rickards, and S.J. Flint. 2008. “The Double Bromodomain Proteins Brd2
and Brd3 Couple Histone Acetylation to Transcription.” Molecular Cell 30 (1): 51–60.
https://doi.org/10.1016/j.molcel.2008.01.018.
Li, Yixuan, and Edward Seto. 2016. “HDACs and HDAC Inhibitors in Cancer Development and
Therapy.” Cold Spring Harbor Perspectives in Medicine 6 (10).
https://doi.org/10.1101/cshperspect.a026831.
Lim, Cheh Peng, and Xinmin Cao. 2006. “Structure, Function, and Regulation of STAT
Proteins.” Molecular BioSystems 2 (11): 536. https://doi.org/10.1039/b606246f.
Lin, Grace, Christopher R LaPensee, Zhaohui S Qin, and Jessica Schwartz. 2014. “Reciprocal
Occupancy of BCL6 and STAT5 on Growth Hormone Target Genes: Contrasting
Transcriptional Outcomes and Promoter-Specific Roles of P300 and HDAC3.” Molecular
and Cellular Endocrinology 395 (1–2): 19–31. https://doi.org/10.1016/j.mce.2014.07.020.
Lin, Richard J., Laszlo Nagy, Satoshi Inoue, Wenlin Shao, Wilson H. Miller, and Ronald M.
Evans. 1998. “Role of the Histone Deacetylase Complex in Acute Promyelocytic
Leukaemia.” Nature 391 (6669): 811–14. https://doi.org/10.1038/35895.
Liu, Suhu, Sarah R. Walker, Erik A. Nelson, Robert Cerulli, Michael Xiang, Patricia A. Toniolo,
Jun Qi, et al. 2014a. “Targeting STAT5 in Hematologic Malignancies through Inhibition of
the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2.” Molecular
90

Cancer Therapeutics 13 (5): 1194–1205. https://doi.org/10.1158/1535-7163.MCT-13-0341.
Liu, Suhu, Sarah R Walker, Erik A Nelson, Robert Cerulli, Michael Xiang, Patricia A Toniolo,
Jun Qi, et al. 2014b. “Targeting STAT5 in Hematologic Malignancies through Inhibition of
the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2.” Molecular
Cancer Therapeutics 13 (5): 1194–1205. https://doi.org/10.1158/1535-7163.MCT-13-0341.
Lu, Panpan, Xiying Qu, Yinzhong Shen, Zhengtao Jiang, Pengfei Wang, Hanxian Zeng, Haiyan
Ji, et al. 2016. “The BET Inhibitor OTX015 Reactivates Latent HIV-1 through P-TEFb.”
https://doi.org/10.1038/srep24100.
Luo, Zhuojuan, Chengqi Lin, and Ali Shilatifard. 2012. “The Super Elongation Complex (SEC)
Family in Transcriptional Control.” Nature Reviews Molecular Cell Biology 13 (9): 543–47.
https://doi.org/10.1038/nrm3417.
Ma, Li, Jin-song Gao, Yingjie Guan, Xiaoyan Shi, Hao Zhang, Marina K. Ayrapetov, Zhe
Zhang, et al. 2010. “Acetylation Modulates Prolactin Receptor Dimerization.” Proceedings
of the National Academy of Sciences of the United States of America 107 (45): 19314.
https://doi.org/10.1073/PNAS.1010253107.
Mackmull, Marie-Therese, Murat Iskar, Luca Parca, Stephan Singer, Peer Bork, Alessandro Ori,
and Martin Beck. 2015. “Histone Deacetylase Inhibitors (HDACi) Cause the Selective
Depletion of Bromodomain Containing Proteins (BCPs).” Molecular & Cellular
Proteomics : MCP 14 (5): 1350–60. https://doi.org/10.1074/mcp.M114.042499.
Mancebo, H S, G Lee, J Flygare, J Tomassini, P Luu, Y Zhu, J Peng, et al. 1997. “P-TEFb
Kinase Is Required for HIV Tat Transcriptional Activation in Vivo and in Vitro.” Genes &
Development 11 (20): 2633–44. http://www.ncbi.nlm.nih.gov/pubmed/9334326.
Manolopoulos, K N, F Karpe, and K N Frayn. 2010. “Gluteofemoral Body Fat as a Determinant
of Metabolic Health.” International Journal of Obesity 34 (6): 949–59.
https://doi.org/10.1038/ijo.2009.286.
Marek, Linda, Alexandra Hamacher, Finn K. Hansen, Krystina Kuna, Holger Gohlke, Matthias
U. Kassack, and Thomas Kurz. 2013. “Histone Deacetylase (HDAC) Inhibitors with a
Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5
with Improved Activity against Chemoresistant Cancer Cells.” Journal of Medicinal
Chemistry 56 (2): 427–36. https://doi.org/10.1021/jm301254q.
McKinsey, T A, C L Zhang, and E N Olson. 2001. “Identification of a Signal-Responsive
Nuclear Export Sequence in Class II Histone Deacetylases.” Molecular and Cellular
Biology 21 (18): 6312–21. https://doi.org/10.1128/mcb.21.18.6312-6321.2001.
Michels, Annemieke A, Alessandro Fraldi, Qintong Li, Todd E Adamson, Franç Ois Bonnet,
Van Trung Nguyen, Stanley C Sedore, et al. 2004. “Binding of the 7SK SnRNA Turns the
HEXIM1 Protein into a P-TEFb (CDK9/Cyclin T) Inhibitor.” The EMBO Journal 23:
91

2608–19. https://doi.org/10.1038/sj.emboj.7600275.
Mills, K D, D A Sinclair, and L Guarente. 1999. “MEC1-Dependent Redistribution of the Sir3
Silencing Protein from Telomeres to DNA Double-Strand Breaks.” Cell 97 (5): 609–20.
http://www.ncbi.nlm.nih.gov/pubmed/10367890.
Mori, Marcelo A., Prashant Raghavan, Thomas Thomou, Jeremie Boucher, Stacey RobidaStubbs, Yazmin Macotela, Steven J. Russell, James L. Kirkland, T. Keith Blackwell, and
C. Ronald Kahn. 2012. “Role of MicroRNA Processing in Adipose Tissue in Stress Defense
and Longevity.” Cell Metabolism 16 (3): 336–47.
https://doi.org/10.1016/J.CMET.2012.07.017.
Murre, Cornelis, Gretchen Bain, Marc A. van Dijk, Isaac Engel, Beth A. Furnari, Mark E.
Massari, James R. Matthews, Melanie W. Quong, Richard R. Rivera, and Maarten H.
Stuiver. 1994. “Structure and Function of Helix-Loop-Helix Proteins.” Biochimica et
Biophysica Acta (BBA) - Gene Structure and Expression 1218 (2): 129–35.
https://doi.org/10.1016/0167-4781(94)90001-9.
Naka, Tetsuji, Masashi Narazaki, Moritoshi Hirata, Tomoshige Matsumoto, Seijiro Minamoto,
Atsufumi Aono, Norihiro Nishimoto, et al. 1997. “Structure and Function of a New STATInduced STAT Inhibitor.” Nature 387 (6636): 924–29. https://doi.org/10.1038/43219.
Nanou, Aikaterini, Chrisavgi Toumpeki, Matthieu D Lavigne, Vassiliki Lazou, Jeroen Demmers,
Triantafillos Paparountas, Dimitris Thanos, and Eleni Katsantoni. 2017. “The Dual Role of
LSD1 and HDAC3 in STAT5-Dependent Transcription Is Determined by Protein
Interactions, Binding Affinities, Motifs and Genomic Positions.” Nucleic Acids Research 45
(1): 142–54. https://doi.org/10.1093/nar/gkw832.
Nechaev, Sergei, and Karen Adelman. 2011. “Pol II Waiting in the Starting Gates: Regulating
the Transition from Transcription Initiation into Productive Elongation.” Biochimica et
Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1809 (1): 34–45.
https://doi.org/10.1016/j.bbagrm.2010.11.001.
Nguyen, Thang Van, Pornpimon Angkasekwinai, Hong Dou, Feng-Ming Lin, Long-Sheng Lu,
Jinke Cheng, Y Eugene Chin, Chen Dong, and Edward T H Yeh. 2012. “SUMO-Specific
Protease 1 Is Critical for Early Lymphoid Development through Regulation of STAT5
Activation.” Molecular Cell 45 (2): 210–21. https://doi.org/10.1016/j.molcel.2011.12.026.
Nicodeme, Edwige, Kate L. Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-wa
Chung, Rohit Chandwani, et al. 2010. “Suppression of Inflammation by a Synthetic Histone
Mimic.” Nature 468 (7327): 1119. https://doi.org/10.1038/NATURE09589.
North, Brian J, and Eric Verdin. 2004. “Sirtuins: Sir2-Related NAD-Dependent Protein
Deacetylases.” Genome Biology 5 (5): 224. https://doi.org/10.1186/GB-2004-5-5-224.
Nusinzon, I., and C. M. Horvath. 2003. “Interferon-Stimulated Transcription and Innate Antiviral
92

Immunity Require Deacetylase Activity and Histone Deacetylase 1.” Proceedings of the
National Academy of Sciences 100 (25): 14742–47.
https://doi.org/10.1073/pnas.2433987100.
Papavassiliou, Athanasios G. 1995. “Transcription Factors.” New England Journal of Medicine
332 (1): 45–47. https://doi.org/10.1056/NEJM199501053320108.
Peng, Jinhong, Wei Dong, Lu Chen, Tingting Zou, Yipeng Qi, and Yingle Liu. 2007. “Brd2 Is a
TBP-Associated Protein and Recruits TBP into E2F-1 Transcriptional Complex in Response
to Serum Stimulation.” Molecular and Cellular Biochemistry 294 (1–2): 45–54.
https://doi.org/10.1007/s11010-006-9223-6.
Pfitzner, Edith, Ruth Jähne, Manuela Wissler, Elisabeth Stoecklin, and Bernd Groner. 1998.
“P300/CREB-Binding Protein Enhances the Prolactin-Mediated Transcriptional Induction
through Direct Interaction with the Transactivation Domain of Stat5, but Does Not
Participate in the Stat5-Mediated Suppression of the Glucocorticoid Response.” Molecular
Endocrinology 12 (10): 1582–93. https://doi.org/10.1210/mend.12.10.0180.
Pillus, L, and J Rine. 1989. “Epigenetic Inheritance of Transcriptional States in S. Cerevisiae.”
Cell 59 (4): 637–47. https://doi.org/10.1016/0092-8674(89)90009-3.
Pinz, Sophia, Samy Unser, Dominik Buob, Philipp Fischer, Belinda Jobst, and Anne Rascle.
2015a. “Deacetylase Inhibitors Repress STAT5-Mediated Transcription by Interfering with
Bromodomain and Extra-Terminal (BET) Protein Function.” Nucleic Acids Research 43
(7): 3524–45. https://doi.org/10.1093/nar/gkv188.
———. 2015b. “Deacetylase Inhibitors Repress STAT5-Mediated Transcription by Interfering
with Bromodomain and Extra-Terminal (BET) Protein Function.” Nucleic Acids Research
43 (7): 3524–45. https://doi.org/10.1093/nar/gkv188.
Potthoff, Matthew J, Hai Wu, Michael A Arnold, John M Shelton, Johannes Backs, John
McAnally, James A Richardson, Rhonda Bassel-Duby, and Eric N Olson. 2007. “Histone
Deacetylase Degradation and MEF2 Activation Promote the Formation of Slow-Twitch
Myofibers.” The Journal of Clinical Investigation 117 (9): 2459–67.
https://doi.org/10.1172/JCI31960.
Pradhan, A D, J E Manson, N Rifai, J E Buring, and P M Ridker. 2001. “C-Reactive Protein,
Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus.” JAMA 286 (3): 327–34.
http://www.ncbi.nlm.nih.gov/pubmed/11466099.
Ptashne, Mark. 1988. “How Eukaryotic Transcriptional Activators Work.” Nature 335 (6192):
683–89. https://doi.org/10.1038/335683a0.
Ram, P A, and D J Waxman. 1999. “SOCS/CIS Protein Inhibition of Growth HormoneStimulated STAT5 Signaling by Multiple Mechanisms.” The Journal of Biological
Chemistry 274 (50): 35553–61. https://doi.org/10.1074/JBC.274.50.35553.
93

Rascle, Anne, James A Johnston, and Bruno Amati. 2003. “Deacetylase Activity Is Required for
Recruitment of the Basal Transcription Machinery and Transactivation by STAT5.”
Molecular and Cellular Biology 23 (12): 4162–73. https://doi.org/10.1128/mcb.23.12.41624173.2003.
Rawlings, Jason S, Kristin M Rosler, and Douglas A Harrison. 2004. “The JAK/STAT Signaling
Pathway.” Journal of Cell Science 117: 1281–83. https://doi.org/10.1242/jcs.00963.
Regna, Nicole L., Cristen B. Chafin, Sarah E. Hammond, Abdul G. Puthiyaveetil, David L.
Caudell, and Christopher M. Reilly. 2014. “Class I and II Histone Deacetylase Inhibition by
ITF2357 Reduces SLE Pathogenesis in Vivo.” Clinical Immunology 151 (1): 29–42.
https://doi.org/10.1016/j.clim.2014.01.002.
Rho, J, S Choi, Y R Seong, J Choi, and D S Im. 2001. “The Arginine-1493 Residue in
QRRGRTGR1493G Motif IV of the Hepatitis C Virus NS3 Helicase Domain Is Essential
for NS3 Protein Methylation by the Protein Arginine Methyltransferase 1.” Journal of
Virology 75 (17): 8031–44. https://doi.org/10.1128/JVI.75.17.8031-8044.2001.
Richard, Allison J., Zhaleh Amini-Vaughan, David M. Ribnicky, and Jacqueline M. Stephens.
2013. “Naringenin Inhibits Adipogenesis and Reduces Insulin Sensitivity and Adiponectin
Expression in Adipocytes.” Evidence-Based Complementary and Alternative Medicine
2013: 1–10. https://doi.org/10.1155/2013/549750.
RICHARD, ALLISON J., HARDY HANG, TIMOTHY D. ALLERTON, CARRIE M. ELKS,
and JACQUELINE M. STEPHENS. 2018. “STAT5 Deficiency in Mature Adipocytes
Results in Metabolically Healthy Adiposity, Reduced Growth Hormone Signaling in
Adipose Tissue, and Decreased Energy Expenditure.” Diabetes 67 (Supplement 1): 271–
OR. https://doi.org/10.2337/db18-271-OR.
Richard, Allison J., Hardy Hang, and Jacqueline M. Stephens. 2017. “Pyruvate Dehydrogenase
Complex (PDC) Subunits Moonlight as Interaction Partners of Phosphorylated STAT5 in
Adipocytes and Adipose Tissue.” Journal of Biological Chemistry 292 (48): 19733–42.
https://doi.org/10.1074/jbc.M117.811794.
Roche, Joëlle, and Philippe Bertrand. 2016. “Inside HDACs with More Selective HDAC
Inhibitors.” European Journal of Medicinal Chemistry 121 (October): 451–83.
https://doi.org/10.1016/J.EJMECH.2016.05.047.
Rogers, Richard S., Curt M. Horvath, and Michael J. Matunis. 2003. “SUMO Modification of
STAT1 and Its Role in PIAS-Mediated Inhibition of Gene Activation.” Journal of
Biological Chemistry 278 (32): 30091–97. https://doi.org/10.1074/jbc.M301344200.
Ruijter, Annemieke J M De, Albert H Van Gennip, Huib N Caron, Stephan Kemp, and Andre ! B
P Van Kuilenburg. 2003. “Histone Deacetylases (HDACs) : Characterization of the
Classical HDAC Family.” Biochem. J. Vol. 370.
94

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1223209/pdf/12429021.pdf.
Ruiz-Ojeda, Francisco Javier, Azahara Iris Rupérez, Carolina Gomez-Llorente, Angel Gil, and
Concepción María Aguilera. 2016. “Cell Models and Their Application for Studying
Adipogenic Differentiation in Relation to Obesity: A Review.” International Journal of
Molecular Sciences 17 (7). https://doi.org/10.3390/ijms17071040.
Sá, Paula Mota de, Allison J. Richard, Hardy Hang, and Jacqueline M. Stephens. 2017.
“Transcriptional Regulation of Adipogenesis.” In Comprehensive Physiology, 7:635–74.
Hoboken, NJ, USA: John Wiley & Sons, Inc. https://doi.org/10.1002/cphy.c160022.
Saely, Christoph H., Kathrin Geiger, and Heinz Drexel. 2012. “Brown versus White Adipose
Tissue: A Mini-Review.” Gerontology 58 (1): 15–23. https://doi.org/10.1159/000321319.
Sakamoto, Shuji, Ramesh Potla, and Andrew C. Larner. 2004. “Histone Deacetylase Activity Is
Required to Recruit RNA Polymerase II to the Promoters of Selected Interferon-Stimulated
Early Response Genes.” Journal of Biological Chemistry 279 (39): 40362–67.
https://doi.org/10.1074/jbc.M406400200.
Sasaki, Atsuo, Hideo Yasukawa, Asuka Suzuki, Shintaro Kamizono, Takanori Syoda, Ichiko
Kinjyo, Mika Sasaki, James A. Johnston, and Akihiko Yoshimura. 1999. “CytokineInducible SH2 Protein-3 (CIS3/SOCS3) Inhibits Janus Tyrosine Kinase by Binding through
the N-Terminal Kinase Inhibitory Region as Well as SH2 Domain.” Genes to Cells 4 (6):
339–51. https://doi.org/10.1046/j.1365-2443.1999.00263.x.
Schmitt-Ney, M, W Doppler, R K Ball, and B Groner. 1991. “Beta-Casein Gene Promoter
Activity Is Regulated by the Hormone-Mediated Relief of Transcriptional Repression and a
Mammary-Gland-Specific Nuclear Factor.” Molecular and Cellular Biology 11 (7): 3745–
55. https://doi.org/10.1128/mcb.11.7.3745.
Schröder, Sebastian, Sungyoo Cho, Lei Zeng, Qiang Zhang, Katrin Kaehlcke, Lily Mak, Joann
Lau, et al. 2012. “Two-Pronged Binding with Bromodomain-Containing Protein 4 Liberates
Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein Complexes.”
The Journal of Biological Chemistry 287 (2): 1090–99.
https://doi.org/10.1074/jbc.M111.282855.
Sebastián, Carlos, Maria Serra, Andrée Yeramian, Neus Serrat, Jorge Lloberas, and Antonio
Celada. 2008. “Deacetylase Activity Is Required for STAT5-Dependent GM-CSF
Functional Activity in Macrophages and Differentiation to Dendritic Cells.” Journal of
Immunology (Baltimore, Md. : 1950) 180 (9): 5898–5906.
http://www.ncbi.nlm.nih.gov/pubmed/18424709.
Sethi, Jaswinder K, and Antonio J Vidal-Puig. 2007. “Thematic Review Series: Adipocyte
Biology. Adipose Tissue Function and Plasticity Orchestrate Nutritional Adaptation.”
Journal of Lipid Research 48 (6): 1253–62. https://doi.org/10.1194/jlr.R700005-JLR200.

95

Shah, Reecha D., Jayashree C. Jagtap, S. Mruthyunjaya, Ganesh V. Shelke, Radha Pujari, Gowry
Das, and Padma Shastry. 2013. “Sodium Valproate Potentiates Staurosporine-Induced
Apoptosis in Neuroblastoma Cells via Akt/Survivin Independently of HDAC Inhibition.”
Journal of Cellular Biochemistry 114 (4): 854–63. https://doi.org/10.1002/jcb.24422.
Shang, Catherine A., and Michael J. Waters. 2003. “Constitutively Active Signal Transducer and
Activator of Transcription 5 Can Replace the Requirement for Growth Hormone in
Adipogenesis of 3T3-F442A Preadipocytes.” Molecular Endocrinology 17 (12): 2494–
2508. https://doi.org/10.1210/me.2003-0139.
Shankaranarayanan, P, P Chaitidis, H Kühn, and S Nigam. 2001. “Acetylation by Histone
Acetyltransferase CREB-Binding Protein/P300 of STAT6 Is Required for Transcriptional
Activation of the 15-Lipoxygenase-1 Gene.” The Journal of Biological Chemistry 276 (46):
42753–60. https://doi.org/10.1074/jbc.M102626200.
Shuai, K, C Schindler, V R Prezioso, and J E Darnell. 1992. “Activation of Transcription by
IFN-Gamma: Tyrosine Phosphorylation of a 91-KD DNA Binding Protein.” Science (New
York, N.Y.) 258 (5089): 1808–12. http://www.ncbi.nlm.nih.gov/pubmed/1281555.
Smith, Edwin, Chengqi Lin, and Ali Shilatifard. 2011. “The Super Elongation Complex (SEC)
and MLL in Development and Disease.” Genes & Development 25 (7): 661–72.
https://doi.org/10.1101/gad.2015411.
Starr, Robyn, Tracy A. Willson, Elizabeth M. Viney, Leecia J. L. Murray, John R. Rayner,
Brendan J. Jenkins, Thomas J. Gonda, et al. 1997. “A Family of Cytokine-Inducible
Inhibitors of Signalling.” Nature 387 (6636): 917–21. https://doi.org/10.1038/43206.
Stathis, Anastasios, and Francesco Bertoni. 2018. “BET Proteins as Targets for Anticancer
Treatment.” https://doi.org/10.1158/2159-8290.CD-17-0605.
Stephens, J M, R F Morrison, and P F Pilch. 1996. “The Expression and Regulation of STATs
during 3T3-L1 Adipocyte Differentiation.” The Journal of Biological Chemistry 271 (18):
10441–44. http://www.ncbi.nlm.nih.gov/pubmed/8631837.
Stephens, J M, and P H Pekala. 1991. “Transcriptional Repression of the GLUT4 and C/EBP
Genes in 3T3-L1 Adipocytes by Tumor Necrosis Factor-Alpha.” The Journal of Biological
Chemistry 266 (32): 21839–45. http://www.ncbi.nlm.nih.gov/pubmed/1939208.
Stephens, Jacqueline M., Jongsoon Lee, and Paul F. Pilch. 1997. “Tumor Necrosis Factor-αInduced Insulin Resistance in 3T3-L1 Adipocytes Is Accompanied by a Loss of Insulin
Receptor Substrate-1 and GLUT4 Expression without a Loss of Insulin Receptor-Mediated
Signal Transduction.” Journal of Biological Chemistry 272 (2): 971–76.
https://doi.org/10.1074/jbc.272.2.971.
Stephens, Jacqueline M. 2012. “The Fat Controller: Adipocyte Development.” PLoS Biology 10
(11): e1001436. https://doi.org/10.1371/journal.pbio.1001436.
96

Struhl, Kevin. 1989. “Helix-Turn-Helix, Zinc-Finger, and Leucine-Zipper Motifs for Eukaryotic
Transcriptional Regulatory Proteins.” Trends in Biochemical Sciences 14 (4): 137–40.
https://doi.org/10.1016/0968-0004(89)90145-X.
Surmi, Bonnie K, and Alyssa H Hasty. 2008. “Macrophage Infiltration into Adipose Tissue:
Initiation, Propagation and Remodeling.” Future Lipidology 3 (5): 545.
https://doi.org/10.2217/17460875.3.5.545.
Sutendra, Gopinath, Adam Kinnaird, Peter Dromparis, Roxane Paulin, Trevor H. Stenson, Alois
Haromy, Kyoko Hashimoto, Nancy Zhang, Eric Flaim, and Evangelos D. Michelakis. 2014.
“A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of AcetylCoA and Histone Acetylation.” Cell 158 (1): 84–97.
https://doi.org/10.1016/J.CELL.2014.04.046.
Taniguchi, Yasushi. 2016. “The Bromodomain and Extra-Terminal Domain (BET) Family:
Functional Anatomy of BET Paralogous Proteins.” International Journal of Molecular
Sciences 17 (11). https://doi.org/10.3390/ijms17111849.
Tasset, Diane, Laszio Tora, Catherine Fromental, Elisabeth Scheer, and Pierre Chambon. 1990.
“Distinct Classes of Transcriptional Activating Domains Function by Different
Mechanisms.” Cell 62 (6): 1177–87. https://doi.org/10.1016/0092-8674(90)90394-T.
Taunton, J, C A Hassig, and S L Schreiber. 1996. “A Mammalian Histone Deacetylase Related
to the Yeast Transcriptional Regulator Rpd3p.” Science (New York, N.Y.) 272 (5260): 408–
11. https://doi.org/10.1126/SCIENCE.272.5260.408.
Teglund, Stephan, Catriona McKay, Erin Schuetz, Jan M van Deursen, Dimitrios Stravopodis,
Demin Wang, Michael Brown, Sara Bodner, Gerard Grosveld, and James N Ihle. 1998.
“Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in
Cytokine Responses.” Cell 93 (5): 841–50. https://doi.org/10.1016/S0092-8674(00)814440.
Thomou, Thomas, Marcelo A. Mori, Jonathan M. Dreyfuss, Masahiro Konishi, Masaji
Sakaguchi, Christian Wolfrum, Tata Nageswara Rao, et al. 2017. “Adipose-Derived
Circulating MiRNAs Regulate Gene Expression in Other Tissues.” Nature 542 (7642): 450–
55. https://doi.org/10.1038/nature21365.
Tissenbaum, Heidi A., and Leonard Guarente. 2001. “Increased Dosage of a Sir-2 Gene Extends
Lifespan in Caenorhabditis Elegans.” Nature 410 (6825): 227–30.
https://doi.org/10.1038/35065638.
Tollet-Egnell, Petra, Amilcar Flores-Morales, Anneli Stavréus-Evers, Lena Sahlin, and Gunnar
Norstedt. 1999. “Growth Hormone Regulation of SOCS-2, SOCS-3, and CIS Messenger
Ribonucleic Acid Expression in the Rat 1.” Endocrinology 140 (8): 3693–3704.
https://doi.org/10.1210/endo.140.8.6878.
97

Trajkovski, Mirko, Jean Hausser, Jürgen Soutschek, Bal Bhat, Akinc Akin, Mihaela Zavolan,
Markus H. Heim, and Markus Stoffel. 2011. “MicroRNAs 103 and 107 Regulate Insulin
Sensitivity.” Nature 474 (7353): 649–53. https://doi.org/10.1038/nature10112.
Trengove, Monique C, and Alister C Ward. 2013. “SOCS Proteins in Development and
Disease.” American Journal of Clinical and Experimental Immunology 2 (1): 1–29.
http://www.ncbi.nlm.nih.gov/pubmed/23885323.
Tsui, Chiahao, Carla Inouye, Michaella Levy, Andrew Lu, Laurence Florens, Michael P
Washburn, and Robert Tjian. 2018. “DCas9-Targeted Locus-Specific Protein Isolation
Method Identifies Histone Gene Regulators.” Proceedings of the National Academy of
Sciences of the United States of America 115 (12): E2734–41.
https://doi.org/10.1073/pnas.1718844115.
Ungureanu, D., Sari Vanhatupa, Juha Grönholm, Jorma J Palvimo, and Olli Silvennoinen. 2005.
“SUMO-1 Conjugation Selectively Modulates STAT1-Mediated Gene Responses.” Blood
106 (1): 224–26. https://doi.org/10.1182/blood-2004-11-4514.
Waldrip, Zachary J, Stephanie D Byrum, Aaron J Storey, Jun Gao, Alicia K Byrd, Samuel G
Mackintosh, Wayne P Wahls, Sean D Taverna, Kevin D Raney, and Alan J Tackett. 2014.
“A CRISPR-Based Approach for Proteomic Analysis of a Single Genomic Locus.”
Epigenetics 9 (9): 1207–11. https://doi.org/10.4161/epi.29919.
Walker, S R, E A Nelson, and D A Frank. 2007. “STAT5 Represses BCL6 Expression by
Binding to a Regulatory Region Frequently Mutated in Lymphomas.” Oncogene 26 (2):
224–33. https://doi.org/10.1038/sj.onc.1209775.
Wang, Biao, Noel Moya, Sherry Niessen, Heather Hoover, Maria M Mihaylova, Reuben J Shaw,
John R Yates, Wolfgang H Fischer, John B Thomas, and Marc Montminy. 2011. “A
Hormone-Dependent Module Regulating Energy Balance.” Cell 145 (4): 596–606.
https://doi.org/10.1016/j.cell.2011.04.013.
Wang, Lan, Alexander Gural, Xiao-Jian Sun, Xinyang Zhao, Fabiana Perna, Gang Huang,
Megan A Hatlen, et al. 2011. “The Leukemogenicity of AML1-ETO Is Dependent on SiteSpecific Lysine Acetylation.” Science (New York, N.Y.) 333 (6043): 765–69.
https://doi.org/10.1126/science.1201662.
Wang, R., P. Cherukuri, and J. Luo. 2005. “Activation of Stat3 Sequence-Specific DNA Binding
and Transcription by P300/CREB-Binding Protein-Mediated Acetylation.” Journal of
Biological Chemistry 280 (12): 11528–34. https://doi.org/10.1074/jbc.M413930200.
Wang, Y., and H. Jiang. 2005. “Identification of a Distal STAT5-Binding DNA Region That
May Mediate Growth Hormone Regulation of Insulin-like Growth Factor-I Gene
Expression.” Journal of Biological Chemistry 280 (12): 10955–63.
https://doi.org/10.1074/jbc.M412808200.
Wang, Yaming, and David E. Levy. 2012. “Comparative Evolutionary Genomics of the STAT
98

Family of Transcription Factors.” JAK-STAT 1 (1): 23–36.
https://doi.org/10.4161/jkst.19418.
Wang, Zhibin, Chongzhi Zang, Kairong Cui, Dustin E Schones, Artem Barski, Weiqun Peng,
and Keji Zhao. 2009. “Genome-Wide Mapping of HATs and HDACs Reveals Distinct
Functions in Active and Inactive Genes.” Cell 138 (5): 1019–31.
https://doi.org/10.1016/j.cell.2009.06.049.
Weisberg, Stuart P, Daniel McCann, Manisha Desai, Michael Rosenbaum, Rudolph L Leibel,
Anthony W Ferrante, and Jr. 2003. “Obesity Is Associated with Macrophage Accumulation
in Adipose Tissue.” The Journal of Clinical Investigation 112 (12): 1796–1808.
https://doi.org/10.1172/JCI19246.
Wieland, Otto H. 1983. “The Mammalian Pyruvate Dehydrogenase Complex: Structure and
Regulation.” In , 123–70. Springer, Berlin, Heidelberg.
https://doi.org/10.1007/BFb0031008.
Woelfle, Joachim, and Peter Rotwein. 2004. “In Vivo Regulation of Growth HormoneStimulated Gene Transcription by STAT5b.” American Journal of PhysiologyEndocrinology and Metabolism 286 (3): E393–401.
https://doi.org/10.1152/ajpendo.00389.2003.
“World Health Organization, Obesity and Overweight.” n.d. Accessed May 9, 2019.
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
“World Health Organization; Diabetes.” n.d. Accessed May 9, 2019. https://www.who.int/newsroom/fact-sheets/detail/diabetes.
Wu, Jun, Pontus Boström, Lauren M. Sparks, Li Ye, Jang Hyun Choi, An-Hoa Giang, Melin
Khandekar, et al. 2012. “Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in
Mouse and Human.” Cell 150 (2): 366–76. https://doi.org/10.1016/J.CELL.2012.05.016.
Xiong, Hua, Wan Du, Yan-Jie Zhang, Jie Hong, Wen-Yu Su, Jie-Ting Tang, Ying-Chao Wang,
Rong Lu, and Jing-Yuan Fang. 2012a. “Trichostatin A, a Histone Deacetylase Inhibitor,
Suppresses JAK2/STAT3 Signaling via Inducing the Promoter-Associated Histone
Acetylation of SOCS1 and SOCS3 in Human Colorectal Cancer Cells.” Molecular
Carcinogenesis 51 (2): 174–84. https://doi.org/10.1002/mc.20777.
———. 2012b. “Trichostatin A, a Histone Deacetylase Inhibitor, Suppresses JAK2/STAT3
Signaling via Inducing the Promoter-Associated Histone Acetylation of SOCS1 and SOCS3
in Human Colorectal Cancer Cells.” Molecular Carcinogenesis 51 (2): 174–84.
https://doi.org/10.1002/mc.20777.
Yadav, Amita, Megha Kataria, Vandana Saini, and Anil Yaday. 2013. “Role of Leptin and
Adiponectin in Insulin Resistance.” Clinica Chimica Acta 417 (February): 80–84.
https://doi.org/10.1016/J.CCA.2012.12.007.
Yamamoto, M., G. Iguchi, H. Fukuoka, K. Suda, H. Bando, M. Takahashi, H. Nishizawa, S.
99

Seino, and Y. Takahashi. 2013. “SIRT1 Regulates Adaptive Response of the Growth
Hormone--Insulin-like Growth Factor-I Axis under Fasting Conditions in Liver.”
Proceedings of the National Academy of Sciences 110 (37): 14948–53.
https://doi.org/10.1073/pnas.1220606110.
Yang, Xiang-Jiao, and Serge Grégoire. 2005. “Class II Histone Deacetylases: From Sequence to
Function, Regulation, and Clinical Implication.” Molecular and Cellular Biology 25 (8):
2873–84. https://doi.org/10.1128/MCB.25.8.2873-2884.2005.
Yoshida, M, M Kijima, M Akita, and T Beppu. 1990. “Potent and Specific Inhibition of
Mammalian Histone Deacetylase Both in Vivo and in Vitro by Trichostatin A.” The Journal
of Biological Chemistry 265 (28): 17174–79.
http://www.ncbi.nlm.nih.gov/pubmed/2211619.
Yoshimura, A, T Ohkubo, T Kiguchi, N A Jenkins, D J Gilbert, N G Copeland, T Hara, and A
Miyajima. 1995. “A Novel Cytokine-Inducible Gene CIS Encodes an SH2-Containing
Protein That Binds to Tyrosine-Phosphorylated Interleukin 3 and Erythropoietin
Receptors.” The EMBO Journal 14 (12): 2816–26.
http://www.ncbi.nlm.nih.gov/pubmed/7796808.
Zhang, Ling, Donna B Badgwell, Jack J Bevers, Karni Schlessinger, Peter J Murray, David E
Levy, Stephanie S Watowich, and Stephanie S. Watowich. 2006. “IL-6 Signaling via the
STAT3/SOCS3 Pathway: Functional Analysis of the Conserved STAT3 N-Domain.”
Molecular and Cellular Biochemistry 288 (1–2): 179–89. https://doi.org/10.1007/s11010006-9137-3.
Zhang, Yiying, Ricardo Proenca, Margherita Maffei, Marisa Barone, Lori Leopold, and Jeffrey
M. Friedman. 1994. “Positional Cloning of the Mouse Obese Gene and Its Human
Homologue.” Nature 372 (6505): 425–32. https://doi.org/10.1038/372425a0.
Zhong, Lou, Siyuan Sun, Sumei Yao, Xiao Han, Mingming Gu, and Jiahai Shi. 2018. “Histone
Deacetylase 5 Promotes the Proliferation and Invasion of Lung Cancer Cells.” Oncology
Reports 40 (4): 2224–32. https://doi.org/10.3892/or.2018.6591.
Zhou, Qiang, Tiandao Li, and David H Price. 2012. “RNA Polymerase II Elongation Control.”
Annual Review of Biochemistry 81: 119–43. https://doi.org/10.1146/annurev-biochem052610-095910.
Zhou, X, V M Richon, R A Rifkind, and P A Marks. 2000. “Identification of a Transcriptional
Repressor Related to the Noncatalytic Domain of Histone Deacetylases 4 and 5.”
Proceedings of the National Academy of Sciences of the United States of America 97 (3):
1056–61. https://doi.org/10.1073/PNAS.97.3.1056.
Zvonic, Sanjin, David J Story, Jacqueline M Stephens, and Randall L Mynatt. 2003. “Growth
Hormone, but Not Insulin, Activates STAT5 Proteins in Adipocytes in Vitro and in Vivo.”
Biochemical and Biophysical Research Communications 302 (2): 359–62.
100

https://doi.org/10.1016/S0006-291X(03)00179-7.

101

Vita
Paula Mota de Sá was born in Sao Paulo, Brazil. She received her bachelor’s degree in
biological sciences from University of Sao Paulo (USP), where she became especially interested
in the biomedical field. In 2013, she was selected for an exchange program in the United States
to study English for one semester at Dillard University in New Orleans, Louisiana. Moreover,
she worked in an immunology research laboratory and studied biological science for one year at
Howard University in Washington, DC. During this exchange program, she also worked as a
summer intern in the cancer field at Amgen, in Thousand Oaks, California, then returned to
Brazil and worked with recombinant proteins for about one year at the University of Sao Paulo.
In August 2015, she moved back to the US to pursue her PhD in Biochemistry at Louisiana State
University (LSU), where she worked in the fields of obesity and type 2 diabetes.
.

102

